WO2007131201A2 - Compounds and compositions as hedgehog pathway modulators - Google Patents

Compounds and compositions as hedgehog pathway modulators Download PDF

Info

Publication number
WO2007131201A2
WO2007131201A2 PCT/US2007/068292 US2007068292W WO2007131201A2 WO 2007131201 A2 WO2007131201 A2 WO 2007131201A2 US 2007068292 W US2007068292 W US 2007068292W WO 2007131201 A2 WO2007131201 A2 WO 2007131201A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
biphenyl
amide
carboxylic acid
pyridin
Prior art date
Application number
PCT/US2007/068292
Other languages
French (fr)
Other versions
WO2007131201A3 (en
Inventor
Wenqi Gao
Jiqing Jiang
Yongqin Wan
Dai Cheng
Dong Han
Xu Wu
Shifeng Pan
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007131201(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA200812916A priority Critical patent/UA93548C2/en
Priority to US12/299,290 priority patent/US8178563B2/en
Priority to JP2009510112A priority patent/JP4891396B2/en
Priority to SM200800056T priority patent/SMP200800056B/en
Priority to EA200870504A priority patent/EA018302B1/en
Priority to MEP-2008-556A priority patent/ME00417B/en
Priority to ES07761921T priority patent/ES2422557T3/en
Priority to NZ572362A priority patent/NZ572362A/en
Priority to PL07761921T priority patent/PL2021328T3/en
Priority to MX2008014190A priority patent/MX2008014190A/en
Priority to AU2007247860A priority patent/AU2007247860C1/en
Priority to BRPI0711333A priority patent/BRPI0711333B8/en
Priority to GEAP200710965A priority patent/GEP20105103B/en
Application filed by Irm Llc filed Critical Irm Llc
Priority to EP07761921A priority patent/EP2021328B1/en
Priority to SI200731266T priority patent/SI2021328T1/en
Priority to CA2650248A priority patent/CA2650248C/en
Priority to DK07761921.1T priority patent/DK2021328T3/en
Publication of WO2007131201A2 publication Critical patent/WO2007131201A2/en
Publication of WO2007131201A3 publication Critical patent/WO2007131201A3/en
Priority to IL194818A priority patent/IL194818A/en
Priority to TNP2008000437A priority patent/TNSN08437A1/en
Priority to NO20085059A priority patent/NO341215B1/en
Priority to HK09106269.2A priority patent/HK1127043A1/en
Priority to US13/443,631 priority patent/US20120196849A1/en
Priority to CY2015054C priority patent/CY2015054I1/en
Priority to LTPA2015051C priority patent/LTC2021328I2/en
Priority to NL300790C priority patent/NL300790I1/nl
Priority to NO20171395A priority patent/NO341889B1/en
Priority to NO2018021C priority patent/NO2018021I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the invention provides a method for modulating the activity of the hedgehog signaling pathway.
  • the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of- function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of- function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
  • the hedgehog signaling pathway is essential for numerous processes such as the control of cell proliferation, differentiation and tissue patterning.
  • the aberrant activity of the hedgehog signaling pathway for example, as a result of enhanced activation, however may have pathological consequences.
  • activation of the hedgehog pathway in adult tissues can result in specific types of cancer that include, but are not limited to, cancers of the brain, muscle and skin, prostrate, medulloblastoma, pancreatic adenocarcinomas and small-cell lung carcinomas.
  • Enhanced activation of the hedgehog signaling pathway contributes to the pathology and/or symptomology of a number of diseases. Accordingly, molecules that modulate the activity of the hedgehog signaling pathway are useful as therapeutic agents in the treatment of such diseases.
  • the present invention provides compounds of Formula
  • Yi and Y 2 are independently selected from N and CR 10 ; wherein R ⁇ 0 is selected from hydrogen, halo, halosubstituted-Ci- 6 alkoxy and -OXNRi 0a Rio b ; wherein Ri Oa and R ⁇ Ob are independently selected from hydrogen and
  • Ri is selected from cyano, halo, Ci-
  • R 2 and R 5 are independently selected from hydrogen, cyano, halo, Ci-
  • R 3 and R 4 are independently selected from hydrogen, halo, cyano, Ci-
  • R 6 and R 7 are independently selected from hydrogen, Ci_ 6 alkyl, halosubstituted-Ci- ⁇ alkyl, and with the proviso that
  • R 6 and R 7 are not both hydrogen
  • R 8 is selected from halo, Ci_ 6 alkyl, halosubstituted-Ci_ 6 alkyl, Ci-
  • R 9 is selected from -S(O) 2 Rn, -C(O)Rn, -OR n , -NR 12a Ri2b and -R 11 ; wherein R 11 is selected from aryl, heteroaryl, cycloalkyl and heterocycloalkyl; R 12a and
  • R 12b are independently selected from and
  • aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R 9 can be optionally substituted with 1 to 3 radicals independently selected from C 5 . ioheteroaryl-Co- 4 alkyl, C 3 _i 2 cycloalkyl and Cs ⁇ heterocycloalkyl;
  • the present invention provides a pharmaceutical composition which contains a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof; or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients.
  • the present invention provides a method of treating a disease in an animal in which modulation of the hedgehog pathway activity, can prevent, inhibit or ameliorate the pathology and/or symptomology of the diseases, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof, or a pharmaceutically acceptable salt thereof.
  • the present invention provides the use of a compound of Formula I in the manufacture of a medicament for treating a disease in an animal in which hedgehog pathway activity, contributes to the pathology and/or symptomology of the disease.
  • the present invention provides a process for preparing compounds of Formula I and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof, and the pharmaceutically acceptable salts thereof. Definitions
  • Alkyl as a group and as a structural element of other groups, for example halo-substituted-alkyl and alkoxy, can be either straight-chained or branched.
  • Ci- 4 -alkoxy includes, methoxy, ethoxy, and the like.
  • Halo-substituted alkyl includes trifluoromethyl, pentafluoroethyl, and the like.
  • Aryl means a monocyclic or fused bicyclic aromatic ring assembly containing six to ten ring carbon atoms.
  • aryl may be phenyl or naphthyl, preferably phenyl.
  • Arylene means a divalent radical derived from an aryl group.
  • Heteroaryl is as defined for aryl above where one or more of the ring members is a heteroatom.
  • Cs_ioheteroaryl is a minimum of 5 members as indicated by the carbon atoms but that these carbon atoms can be replaced by a heteroatom.
  • Cs_ioheteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzo[l,3]dioxole, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, thienyl, etc.
  • Cycloalkyl means a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing the number of ring atoms indicated.
  • C 3 _iocycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
  • Ci_ 4 alkyl or a nitrogen protecting group for example, C 3 _sheterocycloalkyl as used in this application to describe compounds of the invention includes morpholino, pyrrolidinyl, pyrrolidinyl-2-one, piperazinyl, piperidinyl, piperidinylone, l,4-dioxa-8- aza-spiro[4.5]dec-8-yl, thiomorpholino, sulfanomorpholino, sulfonomorpholino, etc.
  • Halogen (or halo) preferably represents chloro or fluoro, but may also be bromo or iodo.
  • Hedgehog gain-of-function refers to an aberrant modification or mutation of a Ptc gene, hedgehog gene, or smoothened gene, or a decrease (or loss) in the level of expression of such a gene, which results in a phenotype which resembles contacting a cell with a hedgehog protein, e.g., aberrant activation of a hedgehog pathway.
  • the gain-of-function may include a loss of the ability of the Ptc gene product to regulate the level of expression of GIi genes, e.g., GIi 1, Gli2, and Gli3.
  • hedgehog gain-of-function is also used herein to refer to any similar cellular phenotype (e.g., exhibiting excess proliferation) which occurs due to an alteration anywhere in the hedgehog signal transduction pathway, including, but not limited to, a modification or mutation of hedgehog itself.
  • a tumor cell with an abnormally high proliferation rate due to activation of the hedgehog signaling pathway would have a "hedgehog gain-of-function" phenotype, even if hedgehog is not mutated in that cell.
  • Patched loss-of-function refers to an aberrant modification or mutation of a Ptc gene, or a decreased level of expression of the gene, which results in a phenotype which resembles contacting a cell with a hedgehog protein, e.g., aberrant activation of a hedgehog pathway.
  • the loss-of-function may include a loss of the ability of the Ptc gene product to regulate the level of expression of GIi genes, e.g., GIi 1, Gli2 and Gli3.
  • GIi gain-of-function refers to an aberrant modification or mutation of a GIi gene, or an increased level of expression of the gene, which results in a phenotype which resembles contacting a cell with a hedgehog protein, e.g., aberrant activation of a hedgehog pathway.
  • “Smoothened gain-of-function” refers to an aberrant modification or mutation of a Smo gene, or an increased level of expression of the gene, which results in a phenotype which resembles contacting a cell with a hedgehog protein, e.g., aberrant activation of a hedgehog pathway.
  • Treating refers to a method of alleviating or abating a disease and/or its attendant symptoms.
  • the present invention relates to the discovery that signal transduction pathways regulated by hedgehog, patched (Ptc), gli and/or smoothened can be modulated by compounds of Formula I.
  • Y 2 are selected from N and CRio; wherein R ⁇ 0 is selected from hydrogen, methyl, fluoro, chloro, bromo, dimethylamino-ethoxy and trifluoromethyl; R 6 and R 7 are independently selected from hydrogen methyl, chloro, fluoro, bromo, trifluoromethyl and methoxy; with the proviso that R 6 and R 7 are not both hydrogen; and R 8 is selected from fluoro, chloro, methyl and trifluoromethyl.
  • Ri is selected from cyano, chloro, fluoro, methyl, ethyl, t-butyl, propyl, isobutyl, isopropyl, isopropyloxy, butoxy, methoxy, dimethyl- amino, ethoxy, methyl-sulfanyl, phenyl, trifluoromethyl, trifluoromethoxy and piperazinyl optionally substituted with up to 2 methyl radicals; R 2 and R 5 are independently selected from hydrogen, chloro, fluoro, cyano, methyl, trifluoromethyl, isopropyloxy, methoxy, ethoxy, trifluoromethoxy and dimethylamino; and R 3 and R 4 are independently selected from hydrogen, chloro, methyl, methoxy and cyano; or either Ri and R 2 or Ri and R 5 together with the phenyl to which they are both attached form quinoxalinyl.
  • R 9 is selected from -S(O) 2 Rn, -ORn, -
  • Rn is selected from thiomorpholino, sulfonomorpholino, sulfanomorpholino, morpholino, cyclohexyl, phenyl, azepan-1-yl, 2- oxopiperazin-1-yl, 1 ,4-oxazepan-4-yl, piperidin-1-yl, tetrahydro-2H-pyran-4-yl, piperidin-3-yl, piperazinyl, pyrrolidinyl and 1,4-diazepan-l-yl;
  • R i2a and Ri 2b are independently selected from isobutyl and hydroxy-ethyl; wherein said thiomorpholino, sulfonomorpholino, sulfanomorpholino, morpholino, cyclohexyl, phenyl, azepan-1-yl, 2-
  • Preferred compounds of Formula I are selected from 4'-cyano-6- methyl-biphenyl-3-carboxylic acid [4-(morpholine-4-sulfonyl)-phenyl]-amide, 4'- cyano- ⁇ -methyl-biphenyl-3-carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)- pyridin-3-yl]-amide, 4'-Cyano-2-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl- pyridin-3-yl)-amide, 4'-Methoxy-2-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl- pyridin-3-yl)-amide, 4'-Methoxy-2-methyl-biphenyl-3-carboxylic acid (4-cyclohexyl- phenyl)-amide, 4'-Methoxy-2-methyl-biphenyl
  • Formula I which interfere with aspects of hedgehog, Ptc, or smoothened signal transduction activity will likewise be capable of inhibiting proliferation (or other biological consequences) in normal cells and/or cells having a patched loss-of- function phenotype, a hedgehog gain-of- function phenotype, a smoothened gain-of- function phenotype or a GIi gain-of-function phenotype.
  • these compounds may be useful for inhibiting hedgehog activity in normal cells, e.g., which do not have a genetic mutation that activates the hedgehog pathway.
  • the compounds are capable of inhibiting at least some of the biological activities of hedgehog proteins, preferably specifically in target cells.
  • the methods of the present invention include the use of compounds of Formula I which agonize Ptc inhibition of hedgehog signaling, such as by inhibiting activation of smoothened or downstream components of the signal pathway, in the regulation of repair and/or functional performance of a wide range of cells, tissues and organs, including normal cells, tissues, and organs, as well as those having the phenotype of Ptc loss-of- function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function.
  • the subject method has therapeutic and cosmetic applications ranging from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle, regulation of lung, liver and other organs arising from the primitive gut, regulation of hematopoietic function, regulation of skin and hair growth, etc.
  • the subject methods can be performed on cells which are provided in culture (in vitro), or on cells in a whole animal (in vivo).
  • the subject method can be to treat epithelial cells having a phenotype of Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function.
  • the subject method can be used in treating or preventing basal cell carcinoma or other hedgehog pathway-related disorders.
  • a compound of Formula I can inhibit activation of a hedgehog pathway by binding to smoothened or its downstream proteins.
  • a subject antagonist may inhibit activation of a hedgehog pathway by binding to patched.
  • the subject method can be used as part of a treatment regimen for malignant medulloblastomas and other primary CNS malignant neuroectodermal tumors.
  • the present invention provides pharmaceutical preparations comprising, as an active ingredient, a hedgehog signaling modulator such as a compound of Formula I, a Ptc agonist, a smoothened antagonist, or downstream hedgehog pathway protein antagonist such as described herein, formulated in an amount sufficient to inhibit, in vivo, proliferation or other biological consequences of Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function.
  • a hedgehog signaling modulator such as a compound of Formula I, a Ptc agonist, a smoothened antagonist, or downstream hedgehog pathway protein antagonist such as described herein
  • the subject treatments using a compound of Formula I, patched agonists, smoothened antagonists, or downstream hedgehog pathway protein antagonists can be effective for both human and animal subjects.
  • Animal subjects to which the invention is applicable extend to both domestic animals and livestock, raised either as pets or for commercial purposes. Examples are dogs, cats, cattle, horses, sheep, hogs, and goats.
  • the present invention makes available methods and compounds for inhibiting activation of the hedgehog signaling pathway, e.g., to inhibit aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain- of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting the cell with a compound of Formula I, in a sufficient amount to agonize a normal Ptc activity, antagonize a normal hedgehog activity, antagonize smoothened activity, or antagonize GIi activity e.g., to reverse or control the aberrant growth state.
  • Members of the Hedgehog family of signaling molecules mediate many important short- and long-range patterning processes during vertebrate development.
  • Pattern formation is the activity by which embryonic cells form ordered spatial arrangements of differentiated tissues.
  • the physical complexity of higher organisms arises during embryogenesis through the interplay of cell-intrinsic lineage and cell-extrinsic signaling.
  • Inductive interactions are essential to embryonic patterning in vertebrate development from the earliest establishment of the body plan, to the patterning of the organ systems, to the generation of diverse cell types during tissue differentiation.
  • the effects of developmental cell interactions are varied: responding cells are diverted from one route of cell differentiation to another by inducing cells that differ from both the uninduced and induced states of the responding cells (inductions). Sometimes cells induce their neighbors to differentiate like themselves (homeogenetic induction); in other cases a cell inhibits its neighbors from differentiating like itself.
  • Cell interactions in early development may be sequential, such that an initial induction between two cell types leads to a progressive amplification of diversity.
  • inductive interactions occur not only in embryos, but in adult cells as well, and can act to establish and maintain morphogenetic patterns as well as induce differentiation.
  • the vertebrate family of hedgehog genes includes three members that exist in mammals, known as Desert (Dhh), Sonic (Shh) and Indian (Ihh) hedgehogs, all of which encode secreted proteins. These various Hedgehog proteins consist of a signal peptide, a highly conserved N-terminal region, and a more divergent C-terminal domain. Biochemical studies have shown that autoproteolytic cleavage of the Hh precursor protein proceeds through an internal thioester intermediate which subsequently is cleaved in a nucleophilic substitution. It is likely that the nucleophile is a small lipophilic molecule which becomes covalently bound to the C-terminal end of the N-peptide, tethering it to the cell surface.
  • An inactive Hedgehog signaling pathway is where the transmembrane protein receptor Patched (Ptc) inhibits the activity of Smoothened (Smo), a seven transmembrane protein.
  • the transcription factor GIi a downstream component of Hh signaling, is prevented from entering the nucleus through interactions with cytoplasmic proteins, including Fused and Suppressor of fused (Sufu). As a consequence, transcriptional activation of Hedgehog target genes is repressed. Activation of the pathway is initiated through binding of any of the three mammalian ligands (Dhh, Shh or Ihh) to Ptc.
  • Ligand binding results in a reversal of the repression of Smo, thereby activating a cascade that leads to the translocation of the active form of the transcription factor GIi to the nucleus.
  • Nuclear GIi activates target gene expression, including Ptc and GIi itself.
  • Hedgehog signaling are sufficient to initiate cancer formation and are required for tumor survival.
  • cancers include, but are not limited to, prostate cancer ("Hedgehog signalling in prostate regeneration, neoplasia and metastasis", Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA., Nature.
  • medulloblastoma (Medulloblastoma growth inhibition by hedgehog pathway blockade", Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA., Science.
  • basal cell carcinoma (Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions", Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, Kon C, Gatchalian C, Porter JA, Rubin LL, Wang FY., Proc Natl Acad Sci U S A.
  • pancreatic cancer (“Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis", Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M., Nature.
  • the present invention further provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, which method comprises administering to said subject a therapeutically effective amount (See, "Administration and Pharmaceutical Compositions", infra) of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • a therapeutically effective amount See, "Administration and Pharmaceutical Compositions", infra
  • the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired.
  • compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents.
  • a therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5mg/kg per body weight.
  • An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5mg to about lOOmg, conveniently administered, e.g. in divided doses up to four times a day or in retard form.
  • Suitable unit dosage forms for oral administration comprise from ca. 1 to 50mg active ingredient.
  • Compounds of the invention can be administered as pharmaceutical compositions by any conventional route, in particular enterally, e.g., orally, e.g., in the form of tablets or capsules, or parenterally, e.g., in the form of injectable solutions or suspensions, topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.
  • Pharmaceutical compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods.
  • oral compositions can be tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
  • diluents e.g., lactose, dextrose, sucrose,
  • compositions can be aqueous isotonic solutions or suspensions, and suppositories can be prepared from fatty emulsions or suspensions.
  • the compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Suitable formulations for transdermal applications include an effective amount of a compound of the present invention with a carrier.
  • a carrier can include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • Matrix transdermal formulations may also be used.
  • Suitable formulations for topical application, e.g., to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • Compounds of the invention can be administered in therapeutically effective amounts in combination with one or more therapeutic agents (pharmaceutical combinations). For example, synergistic effects can occur with immunomodulatory or anti-inflammatory substances or other anti-tumor therapeutic agents. Where the compounds of the invention are administered in conjunction with other therapies, dosages of the co- administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.
  • the invention also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • the kit can comprise instructions for its administration.
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • the term "pharmaceutical combination” as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients.
  • the term "fixed combination” means that the active ingredients, e.g. a compound of Formula I and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • the term “non-fixed combination” means that the active ingredients, e.g. a compound of Formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient.
  • cocktail therapy e.g. the administration of 3 or more active ingredients.
  • the present invention also includes processes for the preparation of compounds of the invention.
  • reactive functional groups for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
  • Conventional protecting groups can be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991.
  • a compound of Formula I can be prepared by reacting a compound of formula 2 (or T) with a compound of formula 3 in the presence of a suitable solvent (e.g., dichloromethane, N,N-dimethylformide or the like), in a temperature range of about -20 to about 100 0 C. The reaction can take up to about 20 hours to complete.
  • a suitable solvent e.g., dichloromethane, N,N-dimethylformide or the like
  • a compound of the invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
  • a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
  • the salt forms of the compounds of the invention can be prepared using salts of the starting materials or intermediates.
  • the free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively.
  • a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
  • a suitable acid e.g., hydrochloric acid, etc.
  • Compounds of the invention in unoxidized form can be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 8O 0 C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
  • a suitable inert organic solvent e.g. acetonitrile, ethanol, aqueous dioxane, or the like
  • Prodrug derivatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol.
  • prodrugs can be prepared by reacting a non- derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1- acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).
  • a suitable carbamylating agent e.g., 1,1- acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like.
  • Hydrates of compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
  • Compounds of the invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of the compounds of the invention, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities.
  • the diastereomers can be separated by chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.
  • the compounds of Formula I can be made by a process, which involves:
  • the present invention is further exemplified, but not limited, by the following example that illustrates the preparation of compounds of Formula I according to the invention.
  • Step 1 To a solution of 3-iodo-4-methyl-benzoic acid (10.0 g, 38.2 mmol) in methanol (70 ml) is added concentrated sulfuric acid (0.5 ml). The reaction mixture is heated at 70 0 C for 48 hours, cooled to room ambient temperature and then concentrated. After that, ethyl acetate (100 ml) and aqueous NaHC ⁇ 3 (saturated, 100 ml) solution are added to the residue. The organic layer is separated and washed again with aqueous NaHC ⁇ 3 (saturated, 100 ml) solution.
  • Step 2 To a round-bottom flask containing 3-iodo-4-methyl- benzoic acid methyl ester (1.38 g, 5.00 mmol), 4-cyanophenylboronic acid (1.10 g, 7.48 mmol), palladium acetate (168 mg, 0.748 mmol), 2-
  • Step 3 To a solution of 4'-cyano-6-methyl-biphenyl-3-carboxylic acid methyl ester 2 (2.56 g, 10.3 mmol) in l,4-dioxane-H 2 O (1:1 mixture, 20 ml) is added NaOH (1.22 g, 30.2 mmol)). The reaction is stirred at ambient temperature for 24 hours. To this mixture is added aqueous HCl (1 N, 36 ml) and it is then extracted with ethyl acetate (40 ml x 3). The organic layers are combined, dried over anhydrous Na 2 SO 4 . The solver is removed.
  • Step 4 To a suspension of 4'-cyano-6-methyl-biphenyl-3-carboxylic acid 3 (40 mg, 0.17 mmol) in anhydrous methylene chloride (5 ml) is added 2 drops of DMF. Then oxalyl chloride (32 mg, 22 ⁇ l, 0.25 mmol) is added. The mixture is stirred at ambient temperature until it turns clear.
  • Step 1 To a solution of 2-chloro-5-nitro-pyridine 4 (2.38 g, 15 mmoL) and cw-2,6-dimethylmorpholine (1.73 g, 15 mmoL) is added K 2 CO 3 (4.14 g, 30 mmoL). The mixture was heated at 50 0 C overnight. After concentration, the residue is partitioned between EtOAc and water. The EtOAc layer is dried over anhydrous Na 2 S ⁇ 4 and concentrated to give crude product 6 as a yellow solid. The crude product is used directly in next step without further purification. LC-MS m/z: 238.1 (M+l).
  • Step 2 The above crude material 6 is hydrogenated in the presence of
  • Step 3 To a solution of 3-bromo-4-methyl benzoic acid (108 mg, 0.5 mmoL), 6-(2,6-Dimethyl-morpholin-4-yl)-pyridin-3-ylamine 7 (104 mg, 0.5 mmoL), amd HATU (190 mg, 0.5 mmoL) in dry DMF (5 mL) is added triethylamine (139 uL, 1.0 mmoL) dropwise. The resulting mixture is stirred at room temperature for 2 h. After concentration, the residue is partitioned between EtOAc and water. The organic layer is dried and concentrated to give the crude product.
  • Compounds of the present invention are assayed to evaluate their capacity to inhibit the hedgehog signaling pathway.
  • ATCC, Manassas, VA are cultured in DMEM/F12 medium (Gibco/Invitrogen, Carlsbad, CA) supplemented with 5% heat inactivated horse serum and 2.5% FBS (Gibco/Invitrogen, Carlsbad, CA ), 50 unit/mL penicillin and 50 ⁇ g/mL of streptomycin (Gibco/Invitrogen, Carlsbad, CA ) at 37 0 C with 5% CO 2 in air atmosphere.
  • TM3 cells were transfected with pTA-8xGli-Luc reporter plasmid. A stably transfected clone termed TMHh- 12 was selected. TMHh- 12 clone showed good response to Shh-N stimulation.
  • IC50s of the antagonists 8000 TMHh-12 cells were plated into each wells in 384-well plates with 50% DMEM/F12 medium supplemented with 2% FBS. After 12 hours, Hh pathway is activated by adding recombinant mouse Shh protein (expressed in E.coli, 8 ⁇ g/mL) or by adding Smo agonists. The testing compounds are added into plates with different concentrations. After 48 hours, the firefly luciferase luciferase activities are assayed with the Bright-GloTM Luciferase Assay System (Promega, Madison, WI). The IC 50 is measured when the effect of the compound reduces the luminescence signal by 50%. Toxicity of these compounds are evaluated in TM3 cells using CeIlTi ter GIo assays or by TM3-Luc cell line (a TM3 cell stably transfected with a constitutive luciferase expression vector).
  • Compounds of Formula I preferably have an EC 50 of less than 50OnM, more preferable less than 20OnM.
  • a cytotoxicity assay is performed to compare the effects of a compound of the invention on medulloblastoma cells (Daoy cells), basal cell carcinoma cells (TE354.T cells) and control cells (human normal fibroblast) according to the following procedure:
  • Daoy cells (medulloblastoma cell line) are purchased from ATCC, and cultured in Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate and 10% FBS at 37 0 C with 5% CO 2 in an air atmosphere.
  • TE354.T cells (from ATCC) are cultured in Dulbecco's modified Eagle's medium with 4 mM L-glutamine fetal bovine serum and 10% of FBS.
  • Normal human dermal fibroblast cells (Clonetics) are cultured in
  • Each of the above cell lines are independently seeded into 96-well plates and cultured to a density of 5,000-10,000 cells/well.
  • a compound of the invention at different concentrations, is added into the cell cultures. After 2 days, the cell viability is evaluated with Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega) following the manufacturer's protocol. The cell viability is directly measured by luminescent signaling and EC 50 S are measured when the signal is inhibited 50%.
  • Compounds of Formula I preferably have an EC 50 of less than 50OnM, more preferable less than 20OnM.

Abstract

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-furiction or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

Description

COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional
Patent Application Number 60/797,949, filed 5 May 2006. The full disclosure of this application is incorporated herein by reference in its entirety and for all purposes.
BACKGROUND
Field of the Invention
[0002] The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of- function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of- function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
Background of the Invention
[0002] During embryonic development, the hedgehog signaling pathway is essential for numerous processes such as the control of cell proliferation, differentiation and tissue patterning. The aberrant activity of the hedgehog signaling pathway, for example, as a result of enhanced activation, however may have pathological consequences. In this regard, activation of the hedgehog pathway in adult tissues can result in specific types of cancer that include, but are not limited to, cancers of the brain, muscle and skin, prostrate, medulloblastoma, pancreatic adenocarcinomas and small-cell lung carcinomas. Enhanced activation of the hedgehog signaling pathway contributes to the pathology and/or symptomology of a number of diseases. Accordingly, molecules that modulate the activity of the hedgehog signaling pathway are useful as therapeutic agents in the treatment of such diseases. Summary of the Invention
[0003] In one aspect, the present invention provides compounds of Formula
I:
Figure imgf000003_0001
I
[0004] in which
[0005] Yi and Y2 are independently selected from N and CR10; wherein Rχ0 is selected from hydrogen, halo,
Figure imgf000003_0002
halosubstituted-Ci-6alkoxy and -OXNRi0aRiob; wherein RiOa and RχOb are independently selected from hydrogen and
Figure imgf000003_0003
[0006] Ri is selected from cyano, halo,
Figure imgf000003_0004
Ci-
6alkoxy,
Figure imgf000003_0005
Cβ-ioaryl, dimethyl-amino,
Figure imgf000003_0006
and C3. gheterocycloalkyl optionally substituted with up to 2
Figure imgf000003_0007
radicals;
[0007] R2 and R5 are independently selected from hydrogen, cyano, halo, Ci-
6alkyl,
Figure imgf000003_0008
and dimethylamino;
[0008] R3 and R4 are independently selected from hydrogen, halo, cyano, Ci-
6alkyl,
Figure imgf000003_0009
and
Figure imgf000003_0010
or either Ri and R2 or Ri and R5 together with the phenyl to which they are both attached form C5. loheteroaryl;
[0009] R6 and R7 are independently selected from hydrogen, Ci_6alkyl, halosubstituted-Ci-βalkyl,
Figure imgf000003_0011
and
Figure imgf000003_0012
with the proviso that
R6 and R7 are not both hydrogen;
[0010] R8 is selected from halo, Ci_6alkyl, halosubstituted-Ci_6alkyl, Ci-
6alkoxy and halosubstituted-Ci-βalkoxy; [0011] R9 is selected from -S(O)2Rn, -C(O)Rn, -ORn, -NR12aRi2b and -R11; wherein R11 is selected from aryl, heteroaryl, cycloalkyl and heterocycloalkyl; R12a and
R12b are independently selected from
Figure imgf000004_0001
and
Figure imgf000004_0002
[0012] wherein said aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R9 can be optionally substituted with 1 to 3 radicals independently selected from
Figure imgf000004_0003
Figure imgf000004_0004
C5. ioheteroaryl-Co-4alkyl, C3_i2cycloalkyl and Cs^heterocycloalkyl;
[0013] wherein said aryl-alkyl substituent of R9 is optionally substituted with
1 to 3 radicals independently selected from halo,
Figure imgf000004_0005
Ci-
6alkoxy,
Figure imgf000004_0006
and methyl-piperazinyl; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof; and the pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds.
[0014] In a second aspect, the present invention provides a pharmaceutical composition which contains a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof; or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients.
[0015] In a third aspect, the present invention provides a method of treating a disease in an animal in which modulation of the hedgehog pathway activity, can prevent, inhibit or ameliorate the pathology and/or symptomology of the diseases, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof, or a pharmaceutically acceptable salt thereof.
[0016] In a fourth aspect, the present invention provides the use of a compound of Formula I in the manufacture of a medicament for treating a disease in an animal in which hedgehog pathway activity, contributes to the pathology and/or symptomology of the disease.
[0017] In a fifth aspect, the present invention provides a process for preparing compounds of Formula I and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof, and the pharmaceutically acceptable salts thereof. Definitions
[0018] "Alkyl" as a group and as a structural element of other groups, for example halo-substituted-alkyl and alkoxy, can be either straight-chained or branched.
Ci-4-alkoxy includes, methoxy, ethoxy, and the like. Halo-substituted alkyl includes trifluoromethyl, pentafluoroethyl, and the like.
[0019] "Aryl" means a monocyclic or fused bicyclic aromatic ring assembly containing six to ten ring carbon atoms. For example, aryl may be phenyl or naphthyl, preferably phenyl. "Arylene" means a divalent radical derived from an aryl group.
[0020] "Heteroaryl" is as defined for aryl above where one or more of the ring members is a heteroatom. For example Cs_ioheteroaryl is a minimum of 5 members as indicated by the carbon atoms but that these carbon atoms can be replaced by a heteroatom. Consequently, Cs_ioheteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzo[l,3]dioxole, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, thienyl, etc.
[0011] "Cycloalkyl" means a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing the number of ring atoms indicated. For example, C3_iocycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
[0012] "Heterocycloalkyl" means cycloalkyl, as defined in this application, provided that one or more of the ring carbons indicated, are replaced by a moiety selected from -O-, -N=, -NR-, -C(O)-, -S-, -S(O) - or -S(O)2-, wherein R is hydrogen,
Ci_4alkyl or a nitrogen protecting group. For example, C3_sheterocycloalkyl as used in this application to describe compounds of the invention includes morpholino, pyrrolidinyl, pyrrolidinyl-2-one, piperazinyl, piperidinyl, piperidinylone, l,4-dioxa-8- aza-spiro[4.5]dec-8-yl, thiomorpholino, sulfanomorpholino, sulfonomorpholino, etc.
[0013] "Halogen" (or halo) preferably represents chloro or fluoro, but may also be bromo or iodo. [0014] "Hedgehog gain-of-function" refers to an aberrant modification or mutation of a Ptc gene, hedgehog gene, or smoothened gene, or a decrease (or loss) in the level of expression of such a gene, which results in a phenotype which resembles contacting a cell with a hedgehog protein, e.g., aberrant activation of a hedgehog pathway. The gain-of-function may include a loss of the ability of the Ptc gene product to regulate the level of expression of GIi genes, e.g., GIi 1, Gli2, and Gli3. The term "hedgehog gain-of-function" is also used herein to refer to any similar cellular phenotype (e.g., exhibiting excess proliferation) which occurs due to an alteration anywhere in the hedgehog signal transduction pathway, including, but not limited to, a modification or mutation of hedgehog itself. For example, a tumor cell with an abnormally high proliferation rate due to activation of the hedgehog signaling pathway would have a "hedgehog gain-of-function" phenotype, even if hedgehog is not mutated in that cell.
[0015] "Patched loss-of-function" refers to an aberrant modification or mutation of a Ptc gene, or a decreased level of expression of the gene, which results in a phenotype which resembles contacting a cell with a hedgehog protein, e.g., aberrant activation of a hedgehog pathway. The loss-of-function may include a loss of the ability of the Ptc gene product to regulate the level of expression of GIi genes, e.g., GIi 1, Gli2 and Gli3.
[0016] "GIi gain-of-function" refers to an aberrant modification or mutation of a GIi gene, or an increased level of expression of the gene, which results in a phenotype which resembles contacting a cell with a hedgehog protein, e.g., aberrant activation of a hedgehog pathway.
[0017] "Smoothened gain-of-function" refers to an aberrant modification or mutation of a Smo gene, or an increased level of expression of the gene, which results in a phenotype which resembles contacting a cell with a hedgehog protein, e.g., aberrant activation of a hedgehog pathway.
[0018] "Treat", "treating" and "treatment" refer to a method of alleviating or abating a disease and/or its attendant symptoms. [0019] The present invention relates to the discovery that signal transduction pathways regulated by hedgehog, patched (Ptc), gli and/or smoothened can be modulated by compounds of Formula I.
Description of Preferred Embodiments
[0020] In one embodiment, with respect to compounds of Formula I, Yi and
Y2 are selected from N and CRio; wherein Rχ0 is selected from hydrogen, methyl, fluoro, chloro, bromo, dimethylamino-ethoxy and trifluoromethyl; R6 and R7 are independently selected from hydrogen methyl, chloro, fluoro, bromo, trifluoromethyl and methoxy; with the proviso that R6 and R7 are not both hydrogen; and R8 is selected from fluoro, chloro, methyl and trifluoromethyl.
[0020] In another embodiment, Ri is selected from cyano, chloro, fluoro, methyl, ethyl, t-butyl, propyl, isobutyl, isopropyl, isopropyloxy, butoxy, methoxy, dimethyl- amino, ethoxy, methyl-sulfanyl, phenyl, trifluoromethyl, trifluoromethoxy and piperazinyl optionally substituted with up to 2 methyl radicals; R2 and R5 are independently selected from hydrogen, chloro, fluoro, cyano, methyl, trifluoromethyl, isopropyloxy, methoxy, ethoxy, trifluoromethoxy and dimethylamino; and R3 and R4 are independently selected from hydrogen, chloro, methyl, methoxy and cyano; or either Ri and R2 or Ri and R5 together with the phenyl to which they are both attached form quinoxalinyl.
[0021] In another embodiment, R9 is selected from -S(O)2Rn, -ORn, -
C(O)Rn, -NRi2aRi2b and -Rn; wherein Rn is selected from thiomorpholino, sulfonomorpholino, sulfanomorpholino, morpholino, cyclohexyl, phenyl, azepan-1-yl, 2- oxopiperazin-1-yl, 1 ,4-oxazepan-4-yl, piperidin-1-yl, tetrahydro-2H-pyran-4-yl, piperidin-3-yl, piperazinyl, pyrrolidinyl and 1,4-diazepan-l-yl; Ri2a and Ri2b are independently selected from isobutyl and hydroxy-ethyl; wherein said thiomorpholino, sulfonomorpholino, sulfanomorpholino, morpholino, cyclohexyl, phenyl, azepan-1-yl, 2-oxopiperazin-l-yl, l,4-oxazepan-4-yl, piperidin-1-yl, tetrahydro-2H-pyran-4-yl, piperidin-3-yl, piperazinyl, pyrrolidinyl or 1,4-diazepan-l-yl of R9 can be optionally substituted with 1 to 3 radicals independently selected from methyl, ethyl, methoxy, benzyl, thienyl-methyl, pyridinyl-methyl, benzo[d][l,3]dioxol-6-yl and 2,3- dihydrobenzo[b][l,4]dioxin-7-yl; wherein said phenyl or benzyl substituent of R9 is optionally substituted with 1 to 3 radicals independently selected from methoxy, ethoxy, methyl-piperazinyl, methyl, trifluoromethoxy, chloro, fluoro and trifluoromethyl.
[0022] Preferred compounds of Formula I are selected from 4'-cyano-6- methyl-biphenyl-3-carboxylic acid [4-(morpholine-4-sulfonyl)-phenyl]-amide, 4'- cyano-ό-methyl-biphenyl-3-carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)- pyridin-3-yl]-amide, 4'-Cyano-2-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl- pyridin-3-yl)-amide, 4'-Methoxy-2-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl- pyridin-3-yl)-amide, 4'-Methoxy-2-methyl-biphenyl-3-carboxylic acid (4-cyclohexyl- phenyl)-amide, 4'-Methoxy-2-methyl-biphenyl-3-carboxylic acid [6-(2-methyl- morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Dimethylamino-2-methyl-biphenyl-3- carboxylic acid (4-cyclohexyl-phenyl)-amide, 4'-Dimethylamino-2-methyl-biphenyl- 3-carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 6-Chloro-4'-dimethylamino- biphenyl-3-carboxylic acid (6-[l,4]oxazepan-4-yl-pyridin-3-yl)-amide, 6-Chloro-4'- dimethylamino-biphenyl-3-carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide, 6- Chloro-4'-dimethylamino-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)- amide, 6-Chloro-4'-methoxy-biphenyl-3-carboxylic acid [6-(2-methyl-morpholin-4- yl)-pyridin-3-yl]-amide, 6-Chloro-4'-methoxy-biphenyl-3-carboxylic acid (6- [l,4]oxazepan-4-yl-pyridin-3-yl)-amide, ό-Chloro^'-methoxy-biphenyl-S-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, ό-Chloro^'-methoxy-biphenyl-S-carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide, 4'-Methoxy-6-methyl-biphenyl-3- carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide, 4'-Methoxy-6-methyl- biphenyl-3-carboxylic acid (6-[l,4]oxazepan-4-yl-pyridin-3-yl)-amide, 4'-Methoxy-6- methyl-biphenyl-3-carboxylic acid [6-(2-methyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Dimethylamino-6-methyl-biphenyl-3-carboxylic acid [6-(2-methyl-morpholin-4- yl)-pyridin-3-yl]-amide, 4'-Dimethylamino-6-methyl-biphenyl-3-carboxylic acid (6- [l,4]oxazepan-4-yl-pyridin-3-yl)-amide, 4'-Dimethylamino-6-methyl-biphenyl-3- carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide, 4'-Methoxy-6-methyl- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Ethoxy-6-methyl- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6-Methyl-4'- methylsulfanyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'- Dimethylamino-ό-methyl-biphenyl-S-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)- amide, 6-Methyl-[l,l';4',l"]terphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)- amide, S'-Chloro-ό-methyl-biphenyl-S-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)- amide, 2',4'-Dichloro-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3- yl)-amide, 2'-Chloro-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3- yl)-amide, S'-Chloro-ό-methyl-biphenyl-S-carboxylic acid (6-azepan- l-yl-pyridin-3- yl)-amide, S'^'-Dichloro-ό-methyl-biphenyl-S-carboxylic acid (6-azepan-l-yl- pyridin-3-yl)-amide, 3'-Chloro-6-methyl-4'-trifluoromethyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6,4'-Dimethyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 4'-Ethyl-6-methyl-biphenyl-3-carboxylic acid (6- azepan-l-yl-pyridin-3-yl)-amide, 4'-tert-Butyl-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 6-Methyl-4'-propyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 4'-Isobutyl-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 4'-Isopropyl-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 6,2',6'-Trimethyl-biphenyl-3-carboxylic acid (6- azepan-l-yl-pyridin-3-yl)-amide, 6,2',3'-Trimethyl-biphenyl-3-carboxylic acid (6- azepan- 1 -yl-pyridin-3-yl)-amide, 6-Methyl-4'-trifluoromethyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6-Methyl-3'-trifluoromethyl-biphenyl-3- carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6-Methyl-3', 5'- bistrifluoromethyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 3'- Isopropoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 3'-Ethoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 2',6'-Dimethoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)- amide, 6-Methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid (6-azepan- 1-yl- pyridin-3-yl)-amide, 6-Methyl-3'-trifluoromethoxy-biphenyl-3-carboxylic acid (6- azepan-l-yl-pyridin-3-yl)-amide, 6-Methyl-biphenyl-3-carboxylic acid (4-morpholin- 4-yl-phenyl)-amide, 4'-Methoxy-6-methyl-biphenyl-3-carboxylic acid (4-morpholin- 4-yl-phenyl)-amide, 3'-Methoxy-6-methyl-biphenyl-3-carboxylic acid (4-morpholin- 4-yl-phenyl)-amide, 4'-(2-Dimethylamino-ethoxy)-6-methyl-biphenyl-3-carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 3'-Dimethylamino-6-methyl-biphenyl-3- carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 4'-Fluoro-6-methyl-biphenyl-3- carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 3'-Fluoro-6-methyl-biphenyl-3- carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 2'-Fluoro-6-methyl-biphenyl-3- carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 4-Methyl-N-(4-morpholin-4-yl- phenyl)-3-quinoxalin-6-yl-benzamide, 6-Methyl-4'-(4-methyl-piperazin-l-yl)- biphenyl-3-carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 2'-Cyano-6-methyl- biphenyl-3-carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 3'-Cyano-6-methyl- biphenyl-3-carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid (6-[l,4]oxazepan-4-yl-pyridin-3-yl)-amide, 4'-Cyano-6- methyl-biphenyl-3 -carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Cyano-6- methyl-biphenyl-3 -carboxylic acid [6-(2-methyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (3,4,5,6-tetrahydro-2H- [l,2']bipyridinyl-5'-yl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (6- morpholin-4-yl-pyridin-3-yl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-methyl-piperazin-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid (3-fluoro-4-morpholin-4-yl-phenyl)-amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid (3-chloro-4-morpholin-4-yl-phenyl)-amide, 4'-Cyano-6- methyl-biphenyl-3 -carboxylic acid (3-bromo-4-morpholin-4-yl-phenyl)-amide, 4'- Cyano-ό-methyl-biphenyl-3-carboxylic acid (3-methyl-4-morpholin-4-yl-phenyl)- amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (4-morpholin-4-yl-3- trifluoromethyl-phenyl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (4- cyclohexyl-phenyl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid biphenyl- 4-ylamide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (4'-methoxy-biphenyl-4- yl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [4-(4-benzyl-piperazin-l- yl)-phenyl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [4-(piperidine-l- sulfonyl)-phenyl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [4- (pyrrolidine-l-sulfonyl)-phenyl]-amide, 4'-Cyano-6-methoxy-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Cyano-2-methoxy-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Cyano-2-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 3'-Fluoro-4'-methoxy-6-methyl-biphenyl-3- carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Isopropoxy-6-methyl- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Butoxy-6-methyl- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 3'-Chloro-4'- methoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'- Methoxy-6,3'-dimethyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)- amide, 4'-Cyano-2-methyl-biphenyl-3-carboxylic acid [4-(piperidine-l-sulfonyl)- phenyl]-amide, 4'-Cyano-6-fluoro-biphenyl-3-carboxylic acid [4-(piperidine-l- sulfonyl)-phenyl]-amide, 6-Bromo-4'-cyano-biphenyl-3-carboxylic acid [4- (piperidine-l-sulfonyl)-phenyl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-benzyl-[l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid [6-(4-thiophen-3-ylmethyl-[l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-2-methyl-biphenyl-3-carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)- pyridin-3-yl]-amide, 4'-Methoxy-2-methyl-biphenyl-3-carboxylic acid [6-(2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, 2-Methyl-4'-trifluoromethyl-biphenyl- 3-carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, 2-Methyl-4'- trifluoromethoxy-biphenyl-3-carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)- pyridin-3-yl]-amide, 4'-Cyano-2-methyl-biphenyl-3-carboxylic acid [6-(2-methyl- morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-2-fluoro-biphenyl-3-carboxylic acid [4-(piperidine-l-sulfonyl)-phenyl]-amide, 4'-Cyano-6-trifluoromethyl-biphenyl-3- carboxylic acid [4-(piperidine-l-sulfonyl)-phenyl]-amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid [6-(4-pyridin-4-ylmethyl-[l,4]diazepan-l-yl)-pyridin-3- yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-3-ylmethyl- [l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2,6-dimethoxy-benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl} -amide, 4'- Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2-ethoxy-benzyl)-[l,4]diazepan-l- yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (6-{4-[2-(4- methyl-piperazin- 1 -yl)-benzyl] - [ 1 ,4]diazepan- 1 -yl } -pyridin-3 -yl)-amide, 4'-Cyano-6- methyl-biphenyl-3-carboxylic acid { 6-[4-(4-methoxy-2,3-dimethyl-benzyl)- [l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-[l,4]diazepan-l-yl]-pyridin-3- yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-2-ylmethyl- [l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-benzo[l,3]dioxol-4-ylmethyl-[l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'- Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2-trifluoromethoxy-benzyl)- [l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2-dimethylamino-benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 4'- Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2-chloro-5-trifluoromethyl- benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid {6-[4-(2,3-difluoro-benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid { 6-[4-(2-chloro-4-fluoro-benzyl)- [l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2,6-difluoro-benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 2-Chloro- 4'-cyano-biphenyl-3-carboxylic acid [4-(piperidine-l-sulfonyl)-phenyl]-amide, 4'- Cyano-o-trifluoromethyl-biphenyl-3-carboxylic acid [6-(2,6-dimethyl-morpholin-4- yl)-pyridin-3-yl]-amide, 2-Chloro-4'-cyano-biphenyl-3-carboxylic acid [6-(2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-ethyl-biphenyl-3- carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-6- methyl-biphenyl-3-carboxylic acid { 6-[4-(3-fluoro-benzyl)-piperazin- l-yl]-pyridin-3- yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2-trifluoromethoxy- benzyl)-piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid {6-[4-(3-chloro-benzyl)-piperazin-l-yl]-pyridin-3-yl}-amide, 4'- Cyano-ό-methyl-biphenyl-3-carboxylic acid {6-[4-(4-isobutyl-benzyl)-piperazin-l- yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(4-tert- butyl-benzyl)-piperazin-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid {6-[4-(7-methoxy-benzo[l,3]dioxol-5-ylmethyl)-piperazin-l-yl]- pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-benzyl- piperazin- l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-3-ylmethyl-piperazin-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid {6-[4-(4-difluoromethoxy-benzyl)-piperazin-l-yl]- pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(4-cyano- benzyl)-piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid [6-(4-quinolin-5-ylmethyl-piperazin-l-yl)-pyridin-3-yl]-amide, 4'- Cyano-ό-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-4-ylmethyl-piperazin- 1-yl)- pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-2- ylmethyl-piperazin-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid {6-[4-(4-imidazol-l-yl-benzyl)-piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(3-cyano-benzyl)-piperazin-l- yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4- isoquinolin-5-ylmethyl-piperazin-l-yl)-pyridin-3-yl]-amide, (R)-2-methyl-N-(6-(2- methylmorpholino)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, 4'- cyano-2-methyl-N-(6-sulfonylmorpholinopyridin-3-yl)biphenyl-3-carboxamide, (S)- 4'-cyano-2-methyl-N-(6-(2-methylmorpholino)pyridin-3-yl)biphenyl-3-carboxamide, (R)-6-chloro-N-(6-(2-methylmorpholino)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl- 3-carboxamide, 4'-cyano-2-methyl-N-(6-sulfinylmorpholinopyridin-3-yl)biphenyl-3- carboxamide, 4'-cyano-N-(6-(diisobutylamino)pyridin-3-yl)-2-methylbiphenyl-3- carboxamide, 4'-cyano-N-(2-((2S,6R)-2,6-dimethylmorpholino)pyrimidin-5-yl)-2- methylbiphenyl-3-carboxamide, N-(2-((2S,6R)-2,6-dimethylmorpholino)pyrimidin-5- yl)-2-methyl-4'-(trifluoromethyl)biphenyl-3-carboxamide, N-(2-((2S,6R)-2,6- dimethylmorpholino)pyrimidin-5-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3- carboxamide, N-(2-(bis(2-hydroxyethyl)amino)pyrimidin-5-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide, 2-methyl-N-(6-(tetrahydro-2H-pyran-4- yloxy)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, N-(5-chloro-6- ((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyltetrahydro- 2H-pyran-4-yl)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide, N-(6-(4-ethylpiperazine-l-carbonyl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide, 2-methyl-N-(6-(2-oxopiperazin-l- yl)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, 2-methyl-N-(6-(l- (pyridin-4-ylmethyl)piperidin-4-yl)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3- carboxamide, 2-methyl-N-(6-(2-oxo-4-(pyridin-4-ylmethyl)piperazin-l-yl)pyridin-3- yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, 2-methyl-N-(6-(l-(pyridin-4- ylmethyl)piperidin-3-yl)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, N-(6-(l-ethylpiperidin-3-yl)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3- carboxamide and N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide.
[0023] It is, therefore, specifically contemplated that compounds of
Formula I which interfere with aspects of hedgehog, Ptc, or smoothened signal transduction activity will likewise be capable of inhibiting proliferation (or other biological consequences) in normal cells and/or cells having a patched loss-of- function phenotype, a hedgehog gain-of- function phenotype, a smoothened gain-of- function phenotype or a GIi gain-of-function phenotype. Thus, it is contemplated that in certain embodiments, these compounds may be useful for inhibiting hedgehog activity in normal cells, e.g., which do not have a genetic mutation that activates the hedgehog pathway. In preferred embodiments, the compounds are capable of inhibiting at least some of the biological activities of hedgehog proteins, preferably specifically in target cells.
[0024] Thus, the methods of the present invention include the use of compounds of Formula I which agonize Ptc inhibition of hedgehog signaling, such as by inhibiting activation of smoothened or downstream components of the signal pathway, in the regulation of repair and/or functional performance of a wide range of cells, tissues and organs, including normal cells, tissues, and organs, as well as those having the phenotype of Ptc loss-of- function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function. For instance, the subject method has therapeutic and cosmetic applications ranging from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle, regulation of lung, liver and other organs arising from the primitive gut, regulation of hematopoietic function, regulation of skin and hair growth, etc. Moreover, the subject methods can be performed on cells which are provided in culture (in vitro), or on cells in a whole animal (in vivo).
[0025] In another embodiment, the subject method can be to treat epithelial cells having a phenotype of Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function. For instance, the subject method can be used in treating or preventing basal cell carcinoma or other hedgehog pathway-related disorders. [0026] In certain embodiments, a compound of Formula I can inhibit activation of a hedgehog pathway by binding to smoothened or its downstream proteins. In certain embodiments, a subject antagonist may inhibit activation of a hedgehog pathway by binding to patched.
[0027] In another preferred embodiment, the subject method can be used as part of a treatment regimen for malignant medulloblastomas and other primary CNS malignant neuroectodermal tumors.
[0028] In another aspect, the present invention provides pharmaceutical preparations comprising, as an active ingredient, a hedgehog signaling modulator such as a compound of Formula I, a Ptc agonist, a smoothened antagonist, or downstream hedgehog pathway protein antagonist such as described herein, formulated in an amount sufficient to inhibit, in vivo, proliferation or other biological consequences of Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function.
[0029] The subject treatments using a compound of Formula I, patched agonists, smoothened antagonists, or downstream hedgehog pathway protein antagonists can be effective for both human and animal subjects. Animal subjects to which the invention is applicable extend to both domestic animals and livestock, raised either as pets or for commercial purposes. Examples are dogs, cats, cattle, horses, sheep, hogs, and goats.
Pharmacology and Utility
[0030] The present invention makes available methods and compounds for inhibiting activation of the hedgehog signaling pathway, e.g., to inhibit aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain- of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting the cell with a compound of Formula I, in a sufficient amount to agonize a normal Ptc activity, antagonize a normal hedgehog activity, antagonize smoothened activity, or antagonize GIi activity e.g., to reverse or control the aberrant growth state. [0031] Members of the Hedgehog family of signaling molecules mediate many important short- and long-range patterning processes during vertebrate development. Pattern formation is the activity by which embryonic cells form ordered spatial arrangements of differentiated tissues. The physical complexity of higher organisms arises during embryogenesis through the interplay of cell-intrinsic lineage and cell-extrinsic signaling. Inductive interactions are essential to embryonic patterning in vertebrate development from the earliest establishment of the body plan, to the patterning of the organ systems, to the generation of diverse cell types during tissue differentiation. The effects of developmental cell interactions are varied: responding cells are diverted from one route of cell differentiation to another by inducing cells that differ from both the uninduced and induced states of the responding cells (inductions). Sometimes cells induce their neighbors to differentiate like themselves (homeogenetic induction); in other cases a cell inhibits its neighbors from differentiating like itself. Cell interactions in early development may be sequential, such that an initial induction between two cell types leads to a progressive amplification of diversity. Moreover, inductive interactions occur not only in embryos, but in adult cells as well, and can act to establish and maintain morphogenetic patterns as well as induce differentiation.
[0032] The vertebrate family of hedgehog genes includes three members that exist in mammals, known as Desert (Dhh), Sonic (Shh) and Indian (Ihh) hedgehogs, all of which encode secreted proteins. These various Hedgehog proteins consist of a signal peptide, a highly conserved N-terminal region, and a more divergent C-terminal domain. Biochemical studies have shown that autoproteolytic cleavage of the Hh precursor protein proceeds through an internal thioester intermediate which subsequently is cleaved in a nucleophilic substitution. It is likely that the nucleophile is a small lipophilic molecule which becomes covalently bound to the C-terminal end of the N-peptide, tethering it to the cell surface. The biological implications are profound. As a result of the tethering, a high local concentration of N-terminal Hedgehog peptide is generated on the surface of the Hedgehog producing cells. It is this N-terminal peptide which is both necessary and sufficient for short- and long-range Hedgehog signaling activities.
[0033] An inactive Hedgehog signaling pathway is where the transmembrane protein receptor Patched (Ptc) inhibits the activity of Smoothened (Smo), a seven transmembrane protein. The transcription factor GIi, a downstream component of Hh signaling, is prevented from entering the nucleus through interactions with cytoplasmic proteins, including Fused and Suppressor of fused (Sufu). As a consequence, transcriptional activation of Hedgehog target genes is repressed. Activation of the pathway is initiated through binding of any of the three mammalian ligands (Dhh, Shh or Ihh) to Ptc. Ligand binding results in a reversal of the repression of Smo, thereby activating a cascade that leads to the translocation of the active form of the transcription factor GIi to the nucleus. Nuclear GIi activates target gene expression, including Ptc and GIi itself.
[0034] Increased levels of Hedgehog signaling are sufficient to initiate cancer formation and are required for tumor survival. These cancers include, but are not limited to, prostate cancer ("Hedgehog signalling in prostate regeneration, neoplasia and metastasis", Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA., Nature. 2004 Oct 7;431(7009):707- 12; "Inhibition of prostate cancer proliferation by interference with SONIC HEDGEH0G-GLI1 signaling", Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, Beyna M, Datta MW, Datta S, Ruiz i Altaba A., Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6), breast cancer ("Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer", Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Nomura M, Kuroki S, Katano M., Cancer Res. 2004 Sep l;64(17):6071-4), medulloblastoma ("Medulloblastoma growth inhibition by hedgehog pathway blockade", Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA., Science. 2002 Aug 30;297(5586):1559-61), basal cell carcinoma ("Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions", Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, Kon C, Gatchalian C, Porter JA, Rubin LL, Wang FY., Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21; "Activating Smoothened mutations in sporadic basal-cell carcinoma", Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, Bonifas JM, Lam CW, Hynes M, Goddard A, Rosenthal A, Epstein EH Jr, de Sauvage FJ., Nature. 1998 Jan l;391(6662):90-2), pancreatic cancer ("Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis", Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M., Nature. 2003 Oct 23;425(6960):851-6; "Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours", Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA., Nature. 2003 Oct 23;425(6960):846-51), and small-cell lung cancer ("Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer", Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB., Nature. 2003 Mar 20;422(6929):313-7).
[0035] In accordance with the foregoing, the present invention further provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, which method comprises administering to said subject a therapeutically effective amount (See, "Administration and Pharmaceutical Compositions", infra) of a compound of Formula I or a pharmaceutically acceptable salt thereof. For any of the above uses, the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired.
Administration and Pharmaceutical Compositions:
[0036] In general, compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5mg to about lOOmg, conveniently administered, e.g. in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 50mg active ingredient. [0037] Compounds of the invention can be administered as pharmaceutical compositions by any conventional route, in particular enterally, e.g., orally, e.g., in the form of tablets or capsules, or parenterally, e.g., in the form of injectable solutions or suspensions, topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form. Pharmaceutical compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods. For example, oral compositions can be tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions can be aqueous isotonic solutions or suspensions, and suppositories can be prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Suitable formulations for transdermal applications include an effective amount of a compound of the present invention with a carrier. A carrier can include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. Matrix transdermal formulations may also be used. Suitable formulations for topical application, e.g., to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives. [0038] Compounds of the invention can be administered in therapeutically effective amounts in combination with one or more therapeutic agents (pharmaceutical combinations). For example, synergistic effects can occur with immunomodulatory or anti-inflammatory substances or other anti-tumor therapeutic agents. Where the compounds of the invention are administered in conjunction with other therapies, dosages of the co- administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.
[0039] The invention also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent. The kit can comprise instructions for its administration. [0040] The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
[0041] The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of Formula I and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of Formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients. Processes for Making Compounds of the Invention
[0042] The present invention also includes processes for the preparation of compounds of the invention. In the reactions described, it can be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991.
[0043] Compounds of Formula I can be prepared by proceeding as in the following Reaction Scheme I:
Reaction Scheme I:
Figure imgf000021_0001
in which Y1, Y2, R1, R2, R3 , R4, R5, R6, R7, Rs and R9 are as defined for Formula I in the Summary of the Invention. A compound of Formula I can be prepared by reacting a compound of formula 2 (or T) with a compound of formula 3 in the presence of a suitable solvent (e.g., dichloromethane, N,N-dimethylformide or the like), in a temperature range of about -20 to about 1000C. The reaction can take up to about 20 hours to complete.
[0044] Detailed examples of the synthesis of compounds of Formula I can be found in the Examples, infra.
Additional Processes for Making Compounds of the Invention [0045] A compound of the invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
[0046] Alternatively, the salt forms of the compounds of the invention can be prepared using salts of the starting materials or intermediates.
[0047] The free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively. For example a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.).
[0048] Compounds of the invention in unoxidized form can be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 8O0C.
[0049] Prodrug derivatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol.
4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non- derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1- acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).
[0050] Protected derivatives of the compounds of the invention can be made by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, "Protecting Groups in Organic Chemistry", 3rd edition, John
Wiley and Sons, Inc., 1999.
[0051] Compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
[0052] Compounds of the invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of the compounds of the invention, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.
[0053] In summary, the compounds of Formula I can be made by a process, which involves:
(a) those of reaction scheme I; and
(b) optionally converting a compound of the invention into a pharmaceutically acceptable salt;
(c) optionally converting a salt form of a compound of the invention to a non-salt form;
(d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide;
(e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form;
(f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers;
99 (g) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and
(h) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.
[0055] Insofar as the production of the starting materials is not particularly described, the compounds are known or can be prepared analogously to methods known in the art or as disclosed in the Examples hereinafter.
[0056] One of skill in the art will appreciate that the above transformations are only representative of methods for preparation of the compounds of the present invention, and that other well known methods can similarly be used.
Examples
[0057] The present invention is further exemplified, but not limited, by the following example that illustrates the preparation of compounds of Formula I according to the invention.
Example 1
4'-cvano-6-methyl-biphenyl-3-carboxylic acid r4-(morpholine-4-sulfonyl)-phenyll- amide
Figure imgf000024_0001
hgand
Figure imgf000024_0002
KF, dioxane
Figure imgf000024_0003
CH2CI2
Figure imgf000024_0004
Figure imgf000024_0005
[0058] Step 1: To a solution of 3-iodo-4-methyl-benzoic acid (10.0 g, 38.2 mmol) in methanol (70 ml) is added concentrated sulfuric acid (0.5 ml). The reaction mixture is heated at 700C for 48 hours, cooled to room ambient temperature and then concentrated. After that, ethyl acetate (100 ml) and aqueous NaHCθ3 (saturated, 100 ml) solution are added to the residue. The organic layer is separated and washed again with aqueous NaHCθ3 (saturated, 100 ml) solution. The organic layer is separated, dried over anhydrous Na2SO4 and concentrated to yield 3-iodo-4-methyl-benzoic acid methyl ester 1. It is used without further purification in the next step. 1H NMR (400 MHz, DMSOd6) δ 8.31 (s, 1 H), 7.87 (d, 1 H, J = 8.4 Hz), 7.48 (d, 1 H, J = 8.4 Hz), 3.85 (s, 3 H), 3.35 (s, 3H); LC-MS m/z: 277.0 (M+l).
[0059] Step 2: To a round-bottom flask containing 3-iodo-4-methyl- benzoic acid methyl ester (1.38 g, 5.00 mmol), 4-cyanophenylboronic acid (1.10 g, 7.48 mmol), palladium acetate (168 mg, 0.748 mmol), 2-
(dicyclohexylphosphino)biphenyl (0.526 g, 1.50 mmol) and potassium fluoride (0.870 g, 15.0 mmol) is added anhydrous 1,4-dioxane (15 ml). The flask is purged with argon and sealed. The mixture is stirred at 1300C for 18 hours, cooled to ambient temperature and then water (20 ml) and ethyl acetate (20 ml) are added. Solid is removed under vacuum filtration. The filtrate is extracted with EtOAc (20 ml x 2). The organic layers are combined, washed with aqueous HCl (5%, 20 ml) and saturated NaHCθ3 (20 ml). It is dried over MgSO4, and concentrated. The residue is purified by silica gel column chromatography (EtOAc/Hexane, gradient) to give 4'- cyano-6-methyl-biphenyl-3-carboxylic acid methyl ester 2; LC-MS m/z: 252.1 (M+l).
[0060] Step 3: To a solution of 4'-cyano-6-methyl-biphenyl-3-carboxylic acid methyl ester 2 (2.56 g, 10.3 mmol) in l,4-dioxane-H2O (1:1 mixture, 20 ml) is added NaOH (1.22 g, 30.2 mmol)). The reaction is stirred at ambient temperature for 24 hours. To this mixture is added aqueous HCl (1 N, 36 ml) and it is then extracted with ethyl acetate (40 ml x 3). The organic layers are combined, dried over anhydrous Na2SO4. The solver is removed. The solid obtained is washed with small amount of acetonitrile and air dried to give 4'-cyano-6-methyl-biphenyl-3-carboxylic acid 3: 1H NMR (DMSOd6) δ 7.94 (d, 2 H, J = 8.0 Hz), 7.84 (dd, 1 H, J1 = 8.4 Hz, J2 = 1.2 Hz), 7.75 (d, 1 H, J = 1.2 Hz), 7.61 (d, 2 H, J = 8.0 Hz), 7.48 (d, 1 H, J = 8.4 Hz), 2.29 (s, 3 H); LC-MS m/z 238.1 (M+l).
[0061] Step 4: To a suspension of 4'-cyano-6-methyl-biphenyl-3-carboxylic acid 3 (40 mg, 0.17 mmol) in anhydrous methylene chloride (5 ml) is added 2 drops of DMF. Then oxalyl chloride (32 mg, 22 μl, 0.25 mmol) is added. The mixture is stirred at ambient temperature until it turns clear. After that, it is concentrated, re- dissolved in anhydrous methylene chloride (3 ml), and added to a solution of 4- (morpholine-4-sulfonyl)-phenylamine (61 mg, 0.25 mmol) and triethylamine (34 mg, 47 μl, 0.33 mmol) in methylene chloride (2 ml). The mixture is stirred for 2 hours, concentrated and the residue is purified by preparative mass triggered HPLC (C18 column, eluted with CH3CN-H2O containing 0.05% TFA) to give 4'-cyano-6-methyl- biphenyl-3-carboxylic acid [4-(morpholine-4-sulfonyl)-phenyl]-amide: 1H NMR (DMSOd6) δ 10.64 (s, 1 H), 8.07(d, 2 H, J = 8.8 Hz), 7.97 (d, 2 H, J = 8.4 Hz), 7.95 (d, 1 H, J = 8.8 Hz), 7.89 (s, 1 H), 7.43 (d, 2 H, J = 8.4 Hz), 7.67 (d, 2 H, J = 8.8 Hz), 7.53 (d, 2 H, J = 8.8 Hz), 3.63 (m, 4 H), 2.84 (m, 4 H) 2.32 (s, 3 H); LC-MS m/z: 462.1 (M+l).
Example 2
4'-cvano-6-methyl-biphenyl-3-carboxyric acid r6-(2,6-dimethyl-morphorin-4-yl)- pvridin-3 - vll -amide
Figure imgf000027_0001
8 Example 2
[0062] Step 1 : To a solution of 2-chloro-5-nitro-pyridine 4 (2.38 g, 15 mmoL) and cw-2,6-dimethylmorpholine (1.73 g, 15 mmoL) is added K2CO3 (4.14 g, 30 mmoL). The mixture was heated at 500C overnight. After concentration, the residue is partitioned between EtOAc and water. The EtOAc layer is dried over anhydrous Na2Sθ4 and concentrated to give crude product 6 as a yellow solid. The crude product is used directly in next step without further purification. LC-MS m/z: 238.1 (M+l).
[0063] Step 2: The above crude material 6 is hydrogenated in the presence of
Pd-C (0.2 g) in MeOH (100 mL) under hydrogen over 10 h. The suspension is filtered through celite and the filtrate is concentrated to give the crude product 7 as a dark brown oil which is used directly in the next step without further purification. LC-MS m/z: 208.1
(M+l).
[0064] Step 3: To a solution of 3-bromo-4-methyl benzoic acid (108 mg, 0.5 mmoL), 6-(2,6-Dimethyl-morpholin-4-yl)-pyridin-3-ylamine 7 (104 mg, 0.5 mmoL), amd HATU (190 mg, 0.5 mmoL) in dry DMF (5 mL) is added triethylamine (139 uL, 1.0 mmoL) dropwise. The resulting mixture is stirred at room temperature for 2 h. After concentration, the residue is partitioned between EtOAc and water. The organic layer is dried and concentrated to give the crude product. The final compound is purified by flash column chromatography using 50% EtOAc in hexane as eluent to give 8 as a white solid. LC-MS m/z: 404.1 (M+l). [0065] Step 4: A mixture of 4-cyanophenyl boronic acid (18 mg, 0.12 mmol),
3-bromo-N-[6-(2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-4-methyl-benzamide 8 (40 mg, O.lmmol), Pd(PPh3)4 (11 mg, 0.01 mmol), and Na2CO3 (42 mg, 0.4 mmol) in a combined solvent system of toluene (0.2 mL) and water (0.2 mL) and ethanol (0.05 mL) is heated at 1400C under microwave irradiation for 30 min. The reaction mixture is diluted with EtOAc and water. The aqueous layer is extracted with EtOAc. The combined organic layer is washed with brine and concentrated to give the crude product which is purified by preparative mass triggered HPLC (Cis column, eluted with CH3CN-H2O containing 0.05% TFA) to give 4'-cyano-6-methyl-biphenyl-3-carboxylic acid [6-(2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide. LC-MS m/z: 427.2 (M+l).
[0066] By repeating the procedures described in the above examples, using appropriate starting materials, the following compounds of Formula I, as identified in Table 1 , are obtained.
Table 1
Compound Number
Figure imgf000028_0001
Figure imgf000029_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000030_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000031_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000032_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000033_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000034_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000035_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000036_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000037_0001
m/z
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000038_0001
m/z
m/z
m/z
m/z
m/z
m/z
Figure imgf000039_0001
Figure imgf000040_0001
m/z
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
)
)
)
)
Figure imgf000048_0001
[0067] Compounds of the present invention are assayed to evaluate their capacity to inhibit the hedgehog signaling pathway.
Gli-Luc Reporter Assay for Hh Pathway Inhibition
[0068] Mouse TM3 cells (obtained from American Type Culture Collection,
ATCC, Manassas, VA) are cultured in DMEM/F12 medium (Gibco/Invitrogen, Carlsbad, CA) supplemented with 5% heat inactivated horse serum and 2.5% FBS (Gibco/Invitrogen, Carlsbad, CA ), 50 unit/mL penicillin and 50 μg/mL of streptomycin (Gibco/Invitrogen, Carlsbad, CA ) at 370C with 5% CO2 in air atmosphere. TM3 cells were transfected with pTA-8xGli-Luc reporter plasmid. A stably transfected clone termed TMHh- 12 was selected. TMHh- 12 clone showed good response to Shh-N stimulation. To evaluate the IC50s of the antagonists, 8000 TMHh-12 cells were plated into each wells in 384-well plates with 50% DMEM/F12 medium supplemented with 2% FBS. After 12 hours, Hh pathway is activated by adding recombinant mouse Shh protein (expressed in E.coli, 8 μg/mL) or by adding Smo agonists. The testing compounds are added into plates with different concentrations. After 48 hours, the firefly luciferase luciferase activities are assayed with the Bright-Glo™ Luciferase Assay System (Promega, Madison, WI). The IC50 is measured when the effect of the compound reduces the luminescence signal by 50%. Toxicity of these compounds are evaluated in TM3 cells using CeIlTi ter GIo assays or by TM3-Luc cell line (a TM3 cell stably transfected with a constitutive luciferase expression vector).
[0069] Compounds of Formula I preferably have an EC50 of less than 50OnM, more preferable less than 20OnM.
Cyto-toxicity Assay
[0070] A cytotoxicity assay is performed to compare the effects of a compound of the invention on medulloblastoma cells (Daoy cells), basal cell carcinoma cells (TE354.T cells) and control cells (human normal fibroblast) according to the following procedure:
[0071] Daoy cells (medulloblastoma cell line) are purchased from ATCC, and cultured in Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate and 10% FBS at 370C with 5% CO2 in an air atmosphere. [0072] TE354.T cells (from ATCC) are cultured in Dulbecco's modified Eagle's medium with 4 mM L-glutamine fetal bovine serum and 10% of FBS. [0073] Normal human dermal fibroblast cells (Clonetics) are cultured in
Fibroblast Growth Medium (Clonetics).
[0074] Each of the above cell lines are independently seeded into 96-well plates and cultured to a density of 5,000-10,000 cells/well. A compound of the invention, at different concentrations, is added into the cell cultures. After 2 days, the cell viability is evaluated with Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega) following the manufacturer's protocol. The cell viability is directly measured by luminescent signaling and EC50S are measured when the signal is inhibited 50%. [0075] Compounds of Formula I preferably have an EC50 of less than 50OnM, more preferable less than 20OnM.
[0076] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

Claims

We Claim:
1. A compound of Formula I:
Figure imgf000051_0001
I in which:
Y] and Y2 are independently selected from N and CRio; wherein Rio is selected from hydrogen, halo, Ci_6alkyl, halosubstituted-Ci_6alkyl, Ci_6alkoxy, halosubstituted-Ci_6alkoxy and -OXNRioaRiob; wherein Rioa and Riob are independently selected from hydrogen and Ci_6alkyl;
R] is selected from cyano, halo, Ci_6alkyl, halosubstituted-Ci_6alkyl, C1- 6alkoxy, halosubstituted-Ci_6alkoxy, Cό-ioaryl, dimethyl-amino, Ci_6alkyl-sulfanyl and C3_8heterocycloalkyl optionally substituted with up to 2 Ci_6alkyl radicals;
R2 and R5 are independently selected from hydrogen, cyano, halo, C1- 6alkyl, halosubstituted-Ci_6alkyl, Ci_6alkoxy, halosubstituted-Ci_6alkoxy and dimethylamino;
R3 and R4 are independently selected from hydrogen, halo, cyano, C1- βalkyl, halosubstituted-Ci_6alkyl, Ci-6alkoxy and halosubstituted-Ci_6alkoxy; or either R] and R2 or R] and R5 together with the phenyl to which they are both attached form C5_ioheteroaryl;
Re and R7 are independently selected from hydrogen, Ci_6alkyl, halosubstituted-Ci_6alkyl, Ci_6alkoxy and halosubstituted-Ci_6alkoxy; with the proviso that Re and R7 are not both hydrogen;
R8 is selected from halo, Ci_6alkyl, halosubstituted-Ci_6alkyl, C1- 6alkoxy and halosubstituted-Ci_6alkoxy; R9 is selected from -S(O)2Rn, -C(O)Rn, -NRi2aRi2b and -Rn; wherein Rn is selected from aryl, heteroaryl, cycloalkyl and heterocycloalkyl; Ri2a and Ri2b are independently selected from Ci_6alkyl and hydroxy-substituted-Ci_6alkyl; wherein said aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R9 can be optionally substituted with 1 to 3 radicals independently selected from Ci_6alkyl, halosubstituted-Ci_6alkyl, Ci_6alkoxy, halosubstituted-Ci_6alkoxy, C6-ioaryl-Co-4alkyl, C5_ioheteroaryl-Co^alkyl, C3_i2cycloalkyl and C3_sheterocycloalkyl; wherein said aryl-alkyl substituent of R9 is optionally substituted with 1 to 3 radicals independently selected from halo, Ci_6alkyl, halosubstituted-Ci_6alkyl, C1- δalkoxy, halosubstituted-Ci_6alkoxy and methyl-piperazinyl; and the pharmaceutically acceptable salts, hydrates, solvates and isomers thereof.
2. The compound of claim 1 in which:
Y] and Y2 are selected from N and CRio; wherein Rio is selected from hydrogen, methyl, fluoro, chloro, bromo, dimethylamino-ethoxy and trifluoromethyl;
R6 and R7 are independently selected from hydrogen methyl, chloro, fluoro, bromo, trifluoromethyl and methoxy; with the proviso that R6 and R7 are not both hydrogen; and
Rs is selected from fluoro, chloro, methyl and trifluoromethyl.
3. The compound of claim 2 in which: R] is selected from cyano, chloro, fluoro, methyl, ethyl, t-butyl, propyl, isobutyl, isopropyl, isopropyloxy, butoxy, methoxy, dimethyl- amino, ethoxy, methyl-sulfanyl, phenyl, trifluoromethyl, trifluoromethoxy and piperazinyl optionally substituted with up to 2 methyl radicals;
R2 and R5 are independently selected from hydrogen, chloro, fluoro, cyano, methyl, trifluoromethyl, isopropyloxy, methoxy, ethoxy, trifluoromethoxy and dimethylamino; and
R3 and R4 are independently selected from hydrogen, chloro, methyl, methoxy and cyano; or either Ri and R2 or Ri and R5 together with the phenyl to which they are both attached form quinoxalinyl.
4. The compound of claim 3 in which Rg is selected from -S(O)2Rn, -ORn, -C(O)Rn, -NRi2aRi2b and -Rn; wherein Rn is selected from thiomorpholino, sulfonomorpholino, sulfanomorpholino, morpholino, cyclohexyl, phenyl, azepan-1-yl, 2-oxopiperazin-l-yl, l,4-oxazepan-4-yl, piperidin-1-yl, tetrahydro-2H-pyran-4-yl, piperidin-3-yl, piperazinyl, pyrrolidinyl and 1,4-diazepan-l-yl; Ri2a and Ri2b are independently selected from isobutyl, hydroxy-ethyl, wherein said thiomorpholino, sulfonomorpholino, sulfanomorpholino, morpholino, cyclohexyl, phenyl, azepan-1-yl, 2-oxopiperazin-l-yl, l,4-oxazepan-4-yl, piperidin-1-yl, tetrahydro-2H-pyran-4-yl, piperidin-3-yl, piperazinyl, pyrrolidinyl or 1,4-diazepan-l-yl of Rg can be optionally substituted with 1 to 3 radicals independently selected from methyl, ethyl, methoxy, benzyl, thienyl-methyl, pyridinyl-methyl, benzo[d][l,3]dioxol-6-yl and 2,3-dihydrobenzo[b][l,4]dioxin-7-yl; wherein said phenyl or benzyl substituent of Rg is optionally substituted with 1 to 3 radicals independently selected from methoxy, ethoxy, methyl-piperazinyl, methyl, trifluoromethoxy, chloro, fluoro and trifluoromethyl.
5. The compound of claim 4 selected from N-(6-((2R,6S)-2,6- dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3- carboxamide, 4'-cyano-6-methyl-biphenyl-3-carboxylic acid [4-(morpholine-4- sulfonyl)-phenyl]-amide, 4'-cyano-6-methyl-biphenyl-3-carboxylic acid [6-(2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-2-methyl-biphenyl-3- carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Methoxy-2-methyl-biphenyl-3- carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Methoxy-2-methyl-biphenyl-3- carboxylic acid (4-cyclohexyl-phenyl)-amide, 4'-Methoxy-2-methyl-biphenyl-3- carboxylic acid [6-(2-methyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'- Dimethylamino-2-methyl-biphenyl-3-carboxylic acid (4-cyclohexyl-phenyl)-amide, 4'-Dimethylamino-2-methyl-biphenyl-3-carboxylic acid (4-morpholin-4-yl-phenyl)- amide, 6-Chloro-4'-dimethylamino-biphenyl-3-carboxylic acid (6-[l,4]oxazepan-4-yl- pyridin-3-yl)-amide, 6-Chloro-4'-dimethylamino-biphenyl-3-carboxylic acid (6- morpholin-4-yl-pyridin-3-yl)-amide, 6-Chloro-4'-dimethylamino-biphenyl-3- carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6-Chloro-4'-methoxy-biphenyl-3- carboxylic acid [6-(2-methyl-morpholin-4-yl)-pyridin-3-yl]-amide, 6-Chloro-4'- methoxy-biphenyl-3-carboxylic acid (6-[l,4]oxazepan-4-yl-pyridin-3-yl)-amide, 6- Chloro-4'-methoxy-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6- Chloro-4'-methoxy-biphenyl-3-carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)- amide, 4'-Methoxy-6-methyl-biphenyl-3-carboxylic acid (6-morpholin-4-yl-pyridin-3- yl)-amide, 4'-Methoxy-6-methyl-biphenyl-3-carboxylic acid (6-[l,4]oxazepan-4-yl- pyridin-3-yl)-amide, 4'-Methoxy-6-methyl-biphenyl-3-carboxylic acid [6-(2-methyl- morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Dimethylamino-6-methyl-biphenyl-3- carboxylic acid [6-(2-methyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'- Dimethylamino-6-methyl-biphenyl-3-carboxylic acid (6-[l,4]oxazepan-4-yl-pyridin- 3-yl)-amide, 4'-Dimethylamino-6-methyl-biphenyl-3-carboxylic acid (6-morpholin-4- yl-pyridin-3-yl)-amide, 4'-Methoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan-l- yl-pyridin-3-yl)-amide, 4'-Ethoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan-l- yl-pyridin-3-yl)-amide, 6-Methyl-4'-methylsulfanyl-biphenyl-3-carboxylic acid (6- azepan-l-yl-pyridin-3-yl)-amide, 4'-Dimethylamino-6-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6-Methyl-[l,l';4',l"]terphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, S'-Chloro-ό-methyl-biphenyl-S-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 2',4'-Dichloro-6-methyl-biphenyl-3- carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 2'-Chloro-6-methyl-biphenyl-3- carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 3'-Chloro-6-methyl-biphenyl-3- carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 3',4'-Dichloro-6-methyl- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 3'-Chloro-6-methyl- 4'-trifluoromethyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6,4'-Dimethyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'- Ethyl-6-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'- tert-Butyl-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 6-Methyl-4'-propyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 4'-Isobutyl-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 4'-Isopropyl-6-methyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 6,2',6'-Trimethyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 6,2',3'-Trimethyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 6- Methyl-4'-trifluoromethyl-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)- amide, ό-Methyl-S'-trifluoromethyl-biphenyl-S-carboxylic acid (6-azepan- 1-yl- pyridin-3-yl)-amide, 6-Methyl-3', S'-bistrifluoromethyl-biphenyl-S-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, S'-Isopropoxy-ό-methyl-biphenyl-S-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 3'-Ethoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan- 1 -yl-pyridin-3 -yl)-amide, 2' ,6 ' -Dimethoxy-ό-methyl-biphenyl-3 - carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6-Methyl-4'-trifluoromethoxy- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 6-Methyl-3'- trifluoromethoxy-biphenyl-3-carboxylic acid (6-azepan- l-yl-pyridin-3-yl)-amide, 6- Methyl-biphenyl-3-carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 4'-Methoxy-6- methyl-biphenyl-3 -carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 3'-Methoxy-6- methyl-biphenyl-3 -carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 4'-(2- Dimethylamino-ethoxy)-6-methyl-biphenyl-3-carboxylic acid (4-morpholin-4-yl- phenyl)-amide, 3'-Dimethylamino-6-methyl-biphenyl-3-carboxylic acid (4-morpholin- 4-yl-phenyl)-amide, 4'-Fluoro-6-methyl-biphenyl-3-carboxylic acid (4-morpholin-4- yl-phenyl)-amide, 3 '-Fluoro-6-methyl-biphenyl-3 -carboxylic acid (4-morpholin-4-yl- phenyl)-amide, 2'-Fluoro-6-methyl-biphenyl-3-carboxylic acid (4-morpholin-4-yl- phenyl)-amide, 4-Methyl-N-(4-morpholin-4-yl-phenyl)-3-quinoxalin-6-yl-benzamide, 6-Methyl-4'-(4-methyl-piperazin-l-yl)-biphenyl-3-carboxylic acid (4-morpholin-4-yl- phenyl)-amide, 2'-Cyano-6-methyl-biphenyl-3-carboxylic acid (4-morpholin-4-yl- phenyl)-amide, S'-Cyano-ό-methyl-biphenyl-S-carboxylic acid (4-morpholin-4-yl- phenyl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (6-[l,4]oxazepan-4-yl- pyridin-3-yl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (6-azepan- 1-yl- pyridin-3-yl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(2-methyl- morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide, 4'-Cyano-6-methyl-biphenyl- 3-carboxylic acid [6-(4-methyl-piperazin-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6- methyl-biphenyl-3 -carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 4'-Cyano-6- methyl-biphenyl-3 -carboxylic acid (3-fluoro-4-morpholin-4-yl-phenyl)-amide, 4'- Cyano-ό-methyl-biphenyl-3-carboxylic acid (3-chloro-4-morpholin-4-yl-phenyl)- amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (3-bromo-4-morpholin-4-yl- phenyl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (3-methyl-4- morpholin-4-yl-phenyl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (4- morpholin-4-yl-3-trifluoromethyl-phenyl)-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid (4-cyclohexyl-phenyl)-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid biphenyl-4-ylamide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid (4'-methoxy-biphenyl-4-yl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [4- (4-benzyl-piperazin-l-yl)-phenyl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [4-(piperidine-l-sulfonyl)-phenyl]-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid [4-(pyrrolidine-l-sulfonyl)-phenyl]-amide, 4'-Cyano-6-methoxy- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Cyano-2-methoxy- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Cyano-2-methyl- biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 3'-Fluoro-4'-methoxy- 6-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'- Isopropoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, 4'-Butoxy-6-methyl-biphenyl-3-carboxylic acid (6-azepan-l-yl-pyridin-3-yl)-amide, S'-Chloro^'-methoxy-ό-methyl-biphenyl-S-carboxylic acid (6-azepan-l-yl-pyridin-3- yl)-amide, 4'-Methoxy-6,3'-dimethyl-biphenyl-3-carboxylic acid (6-azepan-l-yl- pyridin-3-yl)-amide, 4'-Cyano-2-methyl-biphenyl-3-carboxylic acid [4-(piperidine-l- sulfonyl)-phenyl]-amide, 4'-Cyano-6-fluoro-biphenyl-3-carboxylic acid [4- (piperidine-l-sulfonyl)-phenyl]-amide, 6-Bromo-4'-cyano-biphenyl-3-carboxylic acid [4-(piperidine-l-sulfonyl)-phenyl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-benzyl-[l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid [6-(4-thiophen-3-ylmethyl-[l,4]diazepan-l-yl)-pyridin-3- yl]-amide, 4'-Cyano-2-methyl-biphenyl-3-carboxylic acid [6-(2,6-dimethyl- morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Methoxy-2-methyl-biphenyl-3-carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl] -amide, 2-Methyl-4'- trifluoromethyl-biphenyl-3-carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)-pyridin- 3-yl]-amide, 2-Methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-2-methyl-biphenyl-3- carboxylic acid [6-(2-methyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-2-fluoro- biphenyl-3-carboxylic acid [4-(piperidine-l-sulfonyl)-phenyl]-amide, 4'-Cyano-6- trifluoromethyl-biphenyl-3-carboxylic acid [4-(piperidine- l-sulfonyl)-phenyl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-4-ylmethyl- [l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-3-ylmethyl-[l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6- methyl-biphenyl-3-carboxylic acid {6-[4-(2,6-dimethoxy-benzyl)-[l,4]diazepan-l-yl]- pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2-ethoxy- benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid (6- { 4- [2-(4-methyl-piperazin- 1 -yl)-benzyl] - [ 1 ,4]diazepan- 1 -yl } - pyridin-3-yl)-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(4- methoxy-2,3-dimethyl-benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6- methyl-biphenyl-3-carboxylic acid {6-[4-(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)- [l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-2-ylmethyl-[l,4]diazepan-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6- methyl-biphenyl-3-carboxylic acid [6-(4-benzo[l,3]dioxol-4-ylmethyl-[l,4]diazepan- l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2- trifluoromethoxy-benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6- methyl-biphenyl-3 -carboxylic acid { 6- [4-(2-dimethylamino-benzyl)- [ 1 ,4]diazepan- 1 - yl]-pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2- chloro-5-trifluoromethyl-benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl} -amide, 4'-Cyano- 6-methyl-biphenyl-3 -carboxylic acid {6-[4-(2,3-difluoro-benzyl)-[l,4]diazepan-l-yl]- pyridin-3-yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2-chloro- 4-fluoro-benzyl)-[l,4]diazepan-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid {6-[4-(2,6-difluoro-benzyl)-[l,4]diazepan-l-yl]-pyridin-3- yl} -amide, 2-Chloro-4'-cyano-biphenyl-3-carboxylic acid [4-(piperidine-l-sulfonyl)- phenyl]-amide, 4'-Cyano-6-trifluoromethyl-biphenyl-3-carboxylic acid [6-(2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, 2-Chloro-4'-cyano-biphenyl-3- carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, 4'-Cyano-6- ethyl-biphenyl-3 -carboxylic acid [6-(2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]- amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(3-fluoro-benzyl)- piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(2-trifluoromethoxy-benzyl)-piperazin-l-yl]-pyridin-3-yl}-amide, 4'-Cyano-6- methyl-biphenyl-3-carboxylic acid {6-[4-(3-chloro-benzyl)-piperazin-l-yl]-pyridin-3- yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(4-isobutyl-benzyl)- piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(4-tert-butyl-benzyl)-piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid {6-[4-(7-methoxy-benzo[l,3]dioxol-5-ylmethyl)- piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-benzyl-piperazin-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3- carboxylic acid [6-(4-pyridin-3-ylmethyl-piperazin-l-yl)-pyridin-3-yl]-amide, 4'- Cyano-ό-methyl-biphenyl-3-carboxylic acid {6-[4-(4-difluoromethoxy-benzyl)- piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(4-cyano-benzyl)-piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid [6-(4-quinolin-5-ylmethyl-piperazin-l-yl)-pyridin-3-yl]- amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-4-ylmethyl- piperazin- l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-pyridin-2-ylmethyl-piperazin-l-yl)-pyridin-3-yl]-amide, 4'-Cyano-6-methyl- biphenyl-3-carboxylic acid {6-[4-(4-imidazol-l-yl-benzyl)-piperazin-l-yl]-pyridin-3- yl}-amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid {6-[4-(3-cyano-benzyl)- piperazin-l-yl]-pyridin-3-yl} -amide, 4'-Cyano-6-methyl-biphenyl-3-carboxylic acid [6-(4-isoquinolin-5-ylmethyl-piperazin-l-yl)-pyridin-3-yl]-amide, (R)-2-methyl-N-(6- (2-methylmorpholino)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, 4'- cyano-2-methyl-N-(6-sulfonylmorpholinopyridin-3-yl)biphenyl-3-carboxamide, (S)- 4'-cyano-2-methyl-N-(6-(2-methylmorpholino)pyridin-3-yl)biphenyl-3-carboxamide, (R)-6-chloro-N-(6-(2-methylmorpholino)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl- 3-carboxamide, 4'-cyano-2-methyl-N-(6-sulfinylmorpholinopyridin-3-yl)biphenyl-3- carboxamide, 4'-cyano-N-(6-(diisobutylamino)pyridin-3-yl)-2-methylbiphenyl-3- carboxamide, 4'-cyano-N-(2-((2S,6R)-2,6-dimethylmorpholino)pyrimidin-5-yl)-2- methylbiphenyl-3-carboxamide, N-(2-((2S,6R)-2,6-dimethylmorpholino)pyrimidin-5- yl)-2-methyl-4'-(trifluoromethyl)biphenyl-3-carboxamide, N-(2-((2S,6R)-2,6- dimethylmorpholino)pyrimidin-5-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3- carboxamide, N-(2-(bis(2-hydroxyethyl)amino)pyrimidin-5-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide, 2-methyl-N-(6-(tetrahydro-2H-pyran-4- yloxy)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, N-(5-chloro-6- ((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyltetrahydro- 2H-pyran-4-yl)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide,
N-(6-(4-ethylpiperazine-l-carbonyl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide, 2-methyl-N-(6-(2-oxopiperazin-l- yl)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, 2-methyl-N-(6-(l- (pyridin-4-ylmethyl)piperidin-4-yl)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3- carboxamide, 2-methyl-N-(6-(2-oxo-4-(pyridin-4-ylmethyl)piperazin-l-yl)pyridin-3- yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide, 2-methyl-N-(6-(l-(pyridin-4- ylmethyl)piperidin-3-yl)pyridin-3-yl)-4'-(trifluoromethoxy)biphenyl-3-carboxamide and N-(6-(l-ethylpiperidin-3-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide.
6. A method of inhibiting the hedgehog pathway in a cell, comprising contacting the cell with a compound of claim 1.
7. The method of claim 6 wherein the cell has a phenotype of Ptc loss-of- function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of- function.
8. The method of claim 7 wherein the cell is contacted with the hedgehog antagonist in vivo or in vitro.
9. The method of claim 8 wherein the compound is administered to an animal as part of a therapeutic application.
10. The method of claim 9 wherein the therapeutic application is selected from pancreatic cancer, prostrate cancer, medulloblastoma, basal cell carcinoma and small-cell lung cancer.
11. A method for inhibiting unwanted proliferation of a cell, comprising contacting the cell with a compound of claim 1.
12. The method of claim 11 wherein the cell is selected from pancreatic cancer, prostrate cancer, medulloblastoma, basal cell carcinoma and small-cell lung cancer.
PCT/US2007/068292 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators WO2007131201A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
UAA200812916A UA93548C2 (en) 2006-05-05 2007-04-05 Compounds and compositions as hedgehog pathway modulators
GEAP200710965A GEP20105103B (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators
CA2650248A CA2650248C (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators
SI200731266T SI2021328T1 (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators
EA200870504A EA018302B1 (en) 2006-05-05 2007-05-04 Compounds as hedgehog pathway modulators
JP2009510112A JP4891396B2 (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway regulators
ES07761921T ES2422557T3 (en) 2006-05-05 2007-05-04 Compounds and compositions as modulators of the Hedgehog route
NZ572362A NZ572362A (en) 2006-05-05 2007-05-04 Biphenyl compounds and compositions as hedgehog pathway modulators
PL07761921T PL2021328T3 (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators
MX2008014190A MX2008014190A (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators.
AU2007247860A AU2007247860C1 (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators
BRPI0711333A BRPI0711333B8 (en) 2006-05-05 2007-05-04 hedgehog pathway modulators
DK07761921.1T DK2021328T3 (en) 2006-05-05 2007-05-04 Compounds and compositions such as hedgehog (hedgehog) signaling pathway modulators
US12/299,290 US8178563B2 (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators
EP07761921A EP2021328B1 (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators
SM200800056T SMP200800056B (en) 2006-05-05 2007-05-04 Compounds and modulatory compositions of the hedgehog metabolic pathway
MEP-2008-556A ME00417B (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators
IL194818A IL194818A (en) 2006-05-05 2008-10-22 Compounds and compositions as hedgehog pathway modulators
TNP2008000437A TNSN08437A1 (en) 2006-05-05 2008-10-31 Compounds and compositions as hedgehog pathway modulators
NO20085059A NO341215B1 (en) 2006-05-05 2008-12-03 Compounds and compositions such as hedgehog reaction pathway modulators
HK09106269.2A HK1127043A1 (en) 2006-05-05 2009-07-13 Compounds and compositions as hedgehog pathway modulators
US13/443,631 US20120196849A1 (en) 2006-05-05 2012-04-10 Compounds and compositions as hedgehog pathway modulators
CY2015054C CY2015054I1 (en) 2006-05-05 2015-12-14 COMPOUNDS AND COMPOUNDS AS REGULATORS OF HIND CELL PATHWAYS
LTPA2015051C LTC2021328I2 (en) 2006-05-05 2015-12-15 Compounds and compositions as hedgehog path modulators
NL300790C NL300790I1 (en) 2006-05-05 2016-01-13
NO20171395A NO341889B1 (en) 2006-05-05 2017-08-29 Compounds and compositions such as hedgehog reaction pathway modulators
NO2018021C NO2018021I1 (en) 2006-05-05 2018-06-28 sonidegib

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79794906P 2006-05-05 2006-05-05
US60/797,949 2006-05-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/443,631 Division US20120196849A1 (en) 2006-05-05 2012-04-10 Compounds and compositions as hedgehog pathway modulators

Publications (2)

Publication Number Publication Date
WO2007131201A2 true WO2007131201A2 (en) 2007-11-15
WO2007131201A3 WO2007131201A3 (en) 2008-03-06

Family

ID=38668605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/068292 WO2007131201A2 (en) 2006-05-05 2007-05-04 Compounds and compositions as hedgehog pathway modulators

Country Status (46)

Country Link
US (2) US8178563B2 (en)
EP (2) EP2021328B1 (en)
JP (2) JP4891396B2 (en)
KR (1) KR101076943B1 (en)
CN (2) CN102746285B (en)
AR (2) AR060858A1 (en)
AU (1) AU2007247860C1 (en)
BR (1) BRPI0711333B8 (en)
CA (1) CA2650248C (en)
CL (1) CL2007001269A1 (en)
CR (1) CR10399A (en)
CU (1) CU23760B7 (en)
CY (1) CY2015054I1 (en)
DK (1) DK2021328T3 (en)
EA (1) EA018302B1 (en)
EC (1) ECSP088860A (en)
ES (2) ES2552347T3 (en)
GE (1) GEP20105103B (en)
GT (1) GT200800237A (en)
HK (1) HK1127043A1 (en)
HN (1) HN2008001652A (en)
HU (1) HUS1500065I1 (en)
IL (1) IL194818A (en)
JO (1) JO2883B1 (en)
LT (1) LTC2021328I2 (en)
LU (1) LU92883I2 (en)
MA (1) MA30426B1 (en)
ME (1) ME00417B (en)
MX (1) MX2008014190A (en)
MY (1) MY153574A (en)
NL (1) NL300790I1 (en)
NO (3) NO341215B1 (en)
NZ (1) NZ572362A (en)
PE (1) PE20080418A1 (en)
PL (2) PL2021328T3 (en)
PT (2) PT2363393E (en)
RU (1) RU2413718C2 (en)
SG (1) SG172680A1 (en)
SI (1) SI2021328T1 (en)
SM (1) SMP200800056B (en)
SV (1) SV2008003089A (en)
TN (1) TNSN08437A1 (en)
TW (1) TWI369352B (en)
UA (1) UA93548C2 (en)
WO (1) WO2007131201A2 (en)
ZA (1) ZA200808962B (en)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
WO2010033481A1 (en) * 2008-09-17 2010-03-25 Novartis Ag Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
WO2010037715A1 (en) * 2008-10-01 2010-04-08 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2011019798A1 (en) 2009-08-12 2011-02-17 Novartis Ag Methods and compositions for treating leukemia
WO2011062939A1 (en) 2009-11-18 2011-05-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011009852A3 (en) * 2009-07-21 2012-01-19 Novartis Ag Topical pharmaceutical composition including rel-n- [6 - [ (2r, 6s) - 2, 6 - dimethyl - 4 -morpholinyl] -3 - pyridinyl] - 2 -methyl -41 (trifluoromethoxy) - [1,1' -biphenyl] - 3 - carboxamide
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2012097000A1 (en) 2011-01-10 2012-07-19 Pingda Ren Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012166241A1 (en) 2011-06-02 2012-12-06 Novartis Ag Biomarkers for hedgehog inhibitor therapy
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013154878A1 (en) 2012-04-10 2013-10-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014071109A1 (en) 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
TWI448462B (en) * 2008-04-11 2014-08-11 Genentech Inc Pyridyl inhibitors of hedgehog signalling
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014172456A1 (en) 2013-04-17 2014-10-23 Hedgepath, Llc Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
AU2008326381B2 (en) * 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation
US8895576B2 (en) 2006-12-28 2014-11-25 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
WO2014194254A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US9238672B2 (en) 2007-12-27 2016-01-19 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
AU2014280951B2 (en) * 2007-06-07 2016-10-13 Sun Pharmaceutical Industries Limited Biphenylcarboxamide derivatives as hedgehog pathway modulators
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9844541B2 (en) 2012-11-29 2017-12-19 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
US9879293B2 (en) 2009-08-05 2018-01-30 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2021261601A1 (en) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
WO2023211256A1 (en) * 2022-04-29 2023-11-02 제일약품주식회사 Novel pim kinase inhibitors and uses thereof
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA93548C2 (en) * 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
CN101993415B (en) * 2010-09-15 2013-08-14 北京韩美药品有限公司 Compound as Hedgehog path inhibitor, medicine composition containing same and application thereof
US9512106B2 (en) 2012-09-17 2016-12-06 Duke University Smoothened modulators and methods of use thereof
BR112015008480A2 (en) * 2012-10-15 2017-07-04 Epizyme Inc substituted benzene compounds
CN103910736B (en) * 2013-01-08 2017-11-17 江苏先声药业有限公司 A kind of dihydropyran and pyrimidine derivatives and its medical applications
NZ724691A (en) 2014-03-24 2018-02-23 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
CN105906616B (en) * 2015-03-30 2018-09-04 苏州晶云药物科技有限公司 The crystal form and preparation method thereof of LDE225 monophosphates
AU2016271432A1 (en) 2015-06-05 2017-12-07 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
EP3373935B1 (en) 2015-11-12 2021-09-01 Merck Sharp & Dohme Corp. Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof
JOP20190106A1 (en) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (en) 1995-12-01 1999-07-30 Centre Nat Rech Scient NOVEL PURINE DERIVATIVES HAVING IN PARTICULAR ANTI-PROLIFERATIVE PRORIETES AND THEIR BIOLOGICAL APPLICATIONS
AU9781098A (en) 1997-10-02 1999-04-27 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
EP1242366A1 (en) 1999-12-15 2002-09-25 Axys Pharmaceuticals, Inc. Salicylamides as serine protease and factor xa inhibitors
WO2001044260A2 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
AU3540101A (en) 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
KR20030017569A (en) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 Carvedilol
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
JP2002338537A (en) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp Amide compound and its medicinal use
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1545523A1 (en) 2002-07-03 2005-06-29 Astex Technology Limited 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
DE10306250A1 (en) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005020892A2 (en) * 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
CN102060806A (en) 2003-09-11 2011-05-18 iTherX药品公司 Cytokine inhibitors
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
AR046698A1 (en) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha BIFENYLL DERIVATIVE OR ITS SALT, AND PESTICIDE THAT CONTAIN IT AS AN ACTIVE INGREDIENT
EP1715871A1 (en) 2003-12-22 2006-11-02 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
EP1745041B1 (en) * 2004-04-30 2012-06-20 Genentech, Inc. Quinoxaline inhibitors of the hedgehog signalling pathway
US7683097B2 (en) * 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
FR2876583B1 (en) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
ATE502025T1 (en) 2004-10-19 2011-04-15 Compass Pharmaceuticals Llc ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS
GT200500321A (en) 2004-11-09 2006-09-04 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE.
US20080146612A1 (en) 2005-01-27 2008-06-19 Astrazeneca Ab Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
WO2006118914A2 (en) * 2005-04-29 2006-11-09 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
ES2553178T3 (en) 2005-05-18 2015-12-04 Janssen Pharmaceutica N.V. Substituted derivatives of aminopropenyl piperidine or morpholine as new histone deacetylase inhibitors
US7750004B2 (en) 2005-07-07 2010-07-06 Abbott Laboratories Apoptosis promoters
RS51470B (en) * 2005-09-16 2011-04-30 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
UA93548C2 (en) * 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
PE20080948A1 (en) 2006-07-25 2008-09-10 Irm Llc IMIDAZOLE DERIVATIVES AS MODULATORS OF THE HEDGEHOG PATH
EP2617423A1 (en) 2006-10-19 2013-07-24 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
DE102006062203A1 (en) 2006-12-22 2008-06-26 Curacyte Discovery Gmbh Substituted 5H-pyrimido [5,4-b] indoles as inducers of apoptosis in B-CLL cells
JP5373777B2 (en) 2007-06-07 2013-12-18 アイアールエム・リミテッド・ライアビリティ・カンパニー Biphenylcarboxamide derivatives as hedgehog pathway modulators
WO2009009041A2 (en) 2007-07-06 2009-01-15 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
CA2707492A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
WO2009078992A1 (en) 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951083B2 (en) 2006-12-28 2018-04-24 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US10045970B2 (en) 2006-12-28 2018-08-14 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US8895576B2 (en) 2006-12-28 2014-11-25 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US9669011B2 (en) 2006-12-28 2017-06-06 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US9492435B2 (en) 2006-12-28 2016-11-15 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US11007181B2 (en) 2006-12-28 2021-05-18 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US10821102B2 (en) 2006-12-28 2020-11-03 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US10406139B2 (en) 2006-12-28 2019-09-10 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US10314827B2 (en) 2006-12-28 2019-06-11 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US9145422B2 (en) 2006-12-28 2015-09-29 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US11602527B2 (en) 2006-12-28 2023-03-14 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US8507471B2 (en) 2007-06-07 2013-08-13 Irm Llc Biphenylcarboxamide derivatives as hedgehod pathway modulators
AU2014280951B2 (en) * 2007-06-07 2016-10-13 Sun Pharmaceutical Industries Limited Biphenylcarboxamide derivatives as hedgehog pathway modulators
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
CN101820950A (en) * 2007-06-07 2010-09-01 Irm责任有限公司 Biphenylcarboxamide derivatives as hedgehog pathway modulators
AU2008326381B2 (en) * 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation
US9238672B2 (en) 2007-12-27 2016-01-19 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
TWI448462B (en) * 2008-04-11 2014-08-11 Genentech Inc Pyridyl inhibitors of hedgehog signalling
AU2009293444B2 (en) * 2008-09-17 2012-03-15 Sun Pharmaceutical Industries Limited Salts of N-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
JP2012097104A (en) * 2008-09-17 2012-05-24 Novartis Ag SALT OF N-[6-cis-2,6-DIMETHYLMORPHOLIN-4-YL)PYRIDINE-3-YL]-2-METHYL-4'-(TRIFLUOROMETHOXY)[1,1'-BIPHENYL]-3-CARBOXAMIDE
KR101129088B1 (en) 2008-09-17 2012-03-23 노파르티스 아게 Salts of n-[6-cis-2,6-dimethylmorpholin-4-ylpyridine-3-yl]-2-methyl-4'-trifluoromethoxy[1,1'-biphenyl]-3-carboxamide
US8063043B2 (en) 2008-09-17 2011-11-22 Novartis Ag Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
CN102159570A (en) * 2008-09-17 2011-08-17 诺瓦提斯公司 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
EA020048B1 (en) * 2008-09-17 2014-08-29 Новартис Аг Diphosphate salt of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-diphenyl]-3-carboxamide and pharmaceutical composition
WO2010033481A1 (en) * 2008-09-17 2010-03-25 Novartis Ag Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
JP2012502912A (en) * 2008-09-17 2012-02-02 ノバルティス アーゲー N- [6- (cis-2,6-dimethylmorpholin-4-yl) pyridin-3-yl] -2-methyl-4 ′-(trifluoromethoxy) [1,1′-biphenyl] -3-carboxamide Salt
EP2617414A2 (en) * 2008-10-01 2013-07-24 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
AU2009299927B2 (en) * 2008-10-01 2013-05-30 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
WO2010037715A1 (en) * 2008-10-01 2010-04-08 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
JP2015180654A (en) * 2008-10-01 2015-10-15 ノバルティス アーゲー Smoothened antagonism for treatment of hedgehog pathway-related disorders
EP2617414A3 (en) * 2008-10-01 2013-11-06 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
JP2012504573A (en) * 2008-10-01 2012-02-23 ノバルティス アーゲー Smoothened antagonism for the treatment of hedgehog pathway related disorders
KR101624000B1 (en) 2008-10-01 2016-05-24 노파르티스 아게 Smoothened antagonism for the treatment of hedgehog pathway-related disorders
CN103784457A (en) * 2008-10-01 2014-05-14 诺华股份有限公司 Smoothened antagonism for the treatment of hedgehog pathway-related disorders
RU2519200C2 (en) * 2008-10-01 2014-06-10 Новартис Аг Using smoothened antagonists for treating hedgehog pathway related disorders
US8778927B2 (en) 2008-10-01 2014-07-15 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
CN102170873B (en) * 2008-10-01 2014-07-30 诺华股份有限公司 Smoothened antagonism for the treatment of hedgehog pathway-related disorders
EP3023097A1 (en) 2008-10-01 2016-05-25 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2010052448A3 (en) * 2008-11-05 2010-09-10 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
US8722672B2 (en) 2009-07-21 2014-05-13 Novartis Ag Topical pharmaceutical composition including rel-N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4′-(trifluoromethoxY)-[1,1′-biphenyl]-3-carboxamide
WO2011009852A3 (en) * 2009-07-21 2012-01-19 Novartis Ag Topical pharmaceutical composition including rel-n- [6 - [ (2r, 6s) - 2, 6 - dimethyl - 4 -morpholinyl] -3 - pyridinyl] - 2 -methyl -41 (trifluoromethoxy) - [1,1' -biphenyl] - 3 - carboxamide
US9879293B2 (en) 2009-08-05 2018-01-30 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
JP2013501798A (en) * 2009-08-12 2013-01-17 ノバルティス アーゲー Methods and compositions for treating leukemia
WO2011019798A1 (en) 2009-08-12 2011-02-17 Novartis Ag Methods and compositions for treating leukemia
CN102665700A (en) * 2009-11-18 2012-09-12 诺瓦提斯公司 Methods and compositions for treating solid tumors and other malignancies
WO2011062939A1 (en) 2009-11-18 2011-05-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
AU2010322114B2 (en) * 2009-11-18 2014-07-31 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9879025B2 (en) 2010-09-14 2018-01-30 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3581574A1 (en) 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
EP3238722A1 (en) 2011-01-10 2017-11-01 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
WO2012097000A1 (en) 2011-01-10 2012-07-19 Pingda Ren Processes for preparing isoquinolinones and solid forms of isoquinolinones
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
WO2012166241A1 (en) 2011-06-02 2012-12-06 Novartis Ag Biomarkers for hedgehog inhibitor therapy
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013154878A1 (en) 2012-04-10 2013-10-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014071109A1 (en) 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9844541B2 (en) 2012-11-29 2017-12-19 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9962381B2 (en) 2013-04-17 2018-05-08 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of cancerous proliferation disorders using Hedgehog pathway inhibitors
US10328072B2 (en) 2013-04-17 2019-06-25 Hedgepath Pharmaceuticals, Inc. Treatment of lung cancer using hedgehog pathway inhibitors
WO2014172456A1 (en) 2013-04-17 2014-10-23 Hedgepath, Llc Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US9968600B2 (en) 2013-04-17 2018-05-15 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of non-cancerous proliferation disorders using hedgehog pathway inhibitors
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US10363252B2 (en) 2013-04-17 2019-07-30 Hedgepath Pharmaceuticals, Inc. Treatment of prostate cancer using hedgehog pathway inhibitors
WO2014194254A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP3811974A1 (en) 2013-05-30 2021-04-28 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
EP4245376A2 (en) 2014-10-14 2023-09-20 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
US11040053B2 (en) 2015-03-10 2021-06-22 Chinook Therapeutics, Inc. Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US10695344B2 (en) 2015-06-04 2020-06-30 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US11413283B2 (en) 2015-06-04 2022-08-16 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10975114B2 (en) 2017-04-28 2021-04-13 Chinook Therapeutics, Inc. Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
WO2021261601A1 (en) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent
WO2023211256A1 (en) * 2022-04-29 2023-11-02 제일약품주식회사 Novel pim kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
RU2008147663A (en) 2010-06-10
NO341215B1 (en) 2017-09-11
JP4891396B2 (en) 2012-03-07
US20090203666A1 (en) 2009-08-13
NZ572362A (en) 2010-10-29
AU2007247860B2 (en) 2011-06-09
ES2552347T3 (en) 2015-11-27
EA018302B1 (en) 2013-07-30
LU92883I2 (en) 2016-01-20
SV2008003089A (en) 2010-01-12
US20120196849A1 (en) 2012-08-02
UA93548C2 (en) 2011-02-25
SI2021328T1 (en) 2013-08-30
CN102746285A (en) 2012-10-24
SMAP200800056A (en) 2008-10-29
WO2007131201A3 (en) 2008-03-06
BRPI0711333B1 (en) 2020-11-17
SG172680A1 (en) 2011-07-28
LTC2021328I2 (en) 2017-06-26
DK2021328T3 (en) 2013-06-24
IL194818A0 (en) 2009-09-22
AU2007247860A1 (en) 2007-11-15
ME00417B (en) 2011-10-10
HN2008001652A (en) 2011-07-14
LTPA2015051I1 (en) 2015-12-15
PE20080418A1 (en) 2008-06-09
PL2021328T3 (en) 2013-08-30
JP5603308B2 (en) 2014-10-08
CN101437800A (en) 2009-05-20
CN102746285B (en) 2022-01-14
EP2363393A1 (en) 2011-09-07
CU20080202A7 (en) 2011-02-24
EA200870504A1 (en) 2009-04-28
EP2021328A2 (en) 2009-02-11
PL2363393T3 (en) 2016-03-31
MY153574A (en) 2015-02-27
SMP200800056B (en) 2009-11-06
TWI369352B (en) 2012-08-01
IL194818A (en) 2013-12-31
ECSP088860A (en) 2008-12-30
NO20085059L (en) 2009-02-04
AR109423A2 (en) 2018-11-28
CL2007001269A1 (en) 2008-03-14
HK1127043A1 (en) 2009-09-18
RU2413718C2 (en) 2011-03-10
US8178563B2 (en) 2012-05-15
CR10399A (en) 2008-12-03
AR060858A1 (en) 2008-07-16
CU23760B7 (en) 2012-01-31
EP2021328B1 (en) 2013-04-03
GT200800237A (en) 2009-04-29
CY2015054I2 (en) 2016-12-14
CY2015054I1 (en) 2016-12-14
NO341889B1 (en) 2018-02-12
JP2009536220A (en) 2009-10-08
CA2650248C (en) 2011-11-29
ES2422557T3 (en) 2013-09-12
JP2012017333A (en) 2012-01-26
GEP20105103B (en) 2010-10-25
NO20171395A1 (en) 2017-08-29
BRPI0711333A2 (en) 2011-08-30
JO2883B1 (en) 2015-03-15
NL300790I2 (en) 2016-03-15
MX2008014190A (en) 2009-02-04
TW200811132A (en) 2008-03-01
TNSN08437A1 (en) 2010-04-14
KR101076943B1 (en) 2011-10-26
PT2021328E (en) 2013-06-28
ZA200808962B (en) 2009-11-25
EP2363393B1 (en) 2015-08-12
HUS1500065I1 (en) 2016-01-28
NO2018021I1 (en) 2018-06-28
PT2363393E (en) 2015-11-19
AU2007247860C1 (en) 2012-01-12
CA2650248A1 (en) 2007-11-15
KR20080108343A (en) 2008-12-12
BRPI0711333B8 (en) 2021-05-25
MA30426B1 (en) 2009-05-04
NL300790I1 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
EP2363393B1 (en) Compounds and compositions as hedgehog pathway modulators
US8507471B2 (en) Biphenylcarboxamide derivatives as hedgehod pathway modulators
WO2006050351A2 (en) Compounds and compositions as hedgehog pathway modulators
AU2014280951B2 (en) Biphenylcarboxamide derivatives as hedgehog pathway modulators
AU2012202646A1 (en) Biphenylcarboxamide derivatives as hedgehog pathway modulators

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007247860

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2650248

Country of ref document: CA

Ref document number: 194818

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007761921

Country of ref document: EP

Ref document number: CR2008-010399

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 12008502388

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 572362

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008101786

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2009510112

Country of ref document: JP

Ref document number: 200780016150.X

Country of ref document: CN

Ref document number: 08117545

Country of ref document: CO

Ref document number: KR

ENP Entry into the national phase

Ref document number: 10965

Country of ref document: GE

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/014190

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 9437/DELNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007247860

Country of ref document: AU

Date of ref document: 20070504

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2008000698

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200870504

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2008147663

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07761921

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12299290

Country of ref document: US

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0711333

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081105